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ABSTRACT	  
Though transmembrane proteins constitute 30% genes in most organisms and the 
target of nearly 70% of therapeutics, they remain poorly understood. Two hurdles in 
membrane protein characterization are a dearth of antibodies against transmembrane 
protein targets and difficulties in purification. Interaction of antibody fragments with 
transmembrane targets is inferred through a protein complementation assay (PCA), where 
reassembly of two reporter fragments upon binding lends antibiotic resistance. Genetic 
selection of binding members allows engineering against novel targets. 
Oligosaccharyltransferases (OSTs) are chosen as a model for purification and 
characterization. The central enzyme of N-linked glycosylation, OSTs covalently attach a 
glycan to an asparagine residue in a protein substrate. Techniques are demonstrated first 
with bacterial OSTs. Characterization of Lieshmania major OST STT3A is the first case of a 
eukaryotic OST working in vitro. The abilities to target antibodies against and purify 
membrane proteins together constitute tools to elucidate the workings of membrane 
proteins.  
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EXECUTIVE	  SUMMARY	  
Characterization of transmembrane proteins is currently one of the largest open 
problems in protein science.   Though they constitute about 30% of most proteomes by 
sequence and are the target of upwards of 70% of therapeutic drugs, detailed structural and 
mechanistic understanding is lacking for all but a few dozen membrane proteins [1].  The 
relative lack of membrane protein crystal structures (475 of nearly 82,000) highlights the 
dearth of understanding.  The characterization of membrane proteins has remained an open 
problem due to difficulties producing transmembrane proteins in large scales and a lack of 
antibodies targeted against them [1, 2].  This work attempts to improve membrane 
protein characterization in two distinct ways: a suite of techniques for purifying 
and characterizing activity of transmembrane proteins in vitro and a method for 
targeting antibodies against transmembrane proteins in vivo. 
One of the largest barriers to transmembrane protein characterization is difficulty 
overexpressing and purifying target proteins on scales suitable for crystallography and 
activity studies.  Optimization of purification strategies and development of activity assays 
for membrane proteins opens doors to understanding how membrane proteins work [3].  In 
this work, Oligosaccharyltransferases (OSTs) are the primary characterization target 
because they are large and difficult to overexpress, have a detectible activity and have 
valuable applications in biotechnology [4].  Relevant applications of OSTs are centered on 
glycosylation of recombinant proteins produced in Escherichia coli to improve activity, 
stability and targeting [5].  This thesis seeks to develop a purification strategy and in 
vitro activity assay to characterize various OSTs that are interesting and valuable in 
biotechnology. 
Current techniques to engineer antibodies that bind to membrane proteins rely 
heavily on modifications to the target protein’s sequence and protein purification [2, 
6].  Commonly, a solubilized target protein is used to engineer antibodies in vitro, either 
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through infection of a model animal or an immobilization and capture scheme.  Detergent 
solubilized membrane proteins do not always fold into their in vitro conformations, and even 
when they do, these mutants may not always fold in the same conformations as membrane-
integrated wild-type structures [7, 8].  The method used in this project relies on an in 
vivo selection that uses full-length membrane proteins in their native conformations.  As 
such, antibodies against transmembrane proteins engineered with this new method are 
much more likely to bind to physiologically relevant conformations of target proteins. 
With a suite of techniques for obtaining large quantities of high purity, functional 
transmembrane proteins and the ability to engineer antibodies against them, exciting new 
doors are opened for characterization of these difficult targets.  Combining this project’s two 
foci promises exciting new options in chaperone assisted membrane protein crystallography 
and a leap forward in protein drug development [9-11].  Beyond OSTs in this project, 
techniques for overexpression and characterization of transmembrane proteins can be 
applied to poorly characterized but therapeutically valuable proteins.  Chief among future 
targets are G-Protein Coupled Receptors, which represent the target for 36% of therapeutic 
drugs [12].  With this project’s proof of concept in robust characterization and targeting of 
antibodies, a suite of questions that has eluded protein science will be within reach. 
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CHAPTER	  1:	  INTRODUCTION	  
Membrane proteins are currently one of the most difficult classes of proteins to 
study. Though they represent 30% of protein sequences and are the target of nearly 70% of 
therapeutic drugs, very few unique structures have been solved [6]. Membrane proteins 
function as transporters, receptors, enzymes, and structural anchors, often acting as a 
means through which cells are able to perceive the world outside the cytoplasm [1]. 
One of the major hurdles to characterization of membrane proteins is difficulty 
producing sufficiently large and pure samples for crystallization [6]. Membrane proteins 
represent about half of lipid membranes by mass, but a small fraction of the cell mass as a 
whole [1]. Even with an efficient purification protocol, membrane proteins are expressed at 
low levels and overexpression is often toxic to native cells [8]. In the case of eukaryotic 
membrane proteins, many often require post-translational modifications that are not 
possible in bacteria, further complicating expression [8].  
Bacteria are often used as an expression platform for membrane proteins because 
overexpression is often impossible in native hosts [13]. Because of difficulty in 
overexpressing membrane proteins that are properly folded and inserted into the lipid 
bilayer, a few strategies have arisen to circumvent challenges. Often, substantial gains can 
be achieved from selection of appropriate host strain, plasmid, and fusion partner [13, 14]. 
Codon substitutions have emerged as a means to improve membrane protein expression—
though not using the classical approach of merely enriching for the most commonly used 
codons [15]. With improved expression, membrane protein purification must follow, 
bringing its own challenges.  
The standard way to purify membrane proteins involves use of expensive detergents 
to solubilize structures in detergent micelles. One major downside to detergents is the 
inability to predict their success, and the high probability that they will inhibit protein 
function [8]. Most protein crystal structures contain lipid or detergent molecules in the high-
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resolution structures, in very much the same way that water molecules are often included in 
the structures of soluble proteins. Indeed, studies have shed some light on the importance 
of detergent selection based on apparent protein structure [7]. For the most part, detergent 
selection comes down to trying a number of options and happenstance [6]. 
Transmembrane proteins that transmit signals from extracellular stimuli to elicit an 
intracellular response are convenient drug targets because they allow therapeutic molecules 
to act outside the cell [16]. Though they are currently the targets of most therapeutics, 
identification of new ligands remains an open problem [12]. Improved tools for 
overexpression and purification hold promise to facilitate characterization of thus far elusive 
transmembrane protein targets [17]. Of particular interest in membrane protein drug 
targets are G-protein coupled receptors (GPCRs). 
Within membrane proteins, the superfamily of GPCRs constitutes roughly half of 
membrane protein drug targets, or 36% of all drug targets [12]. However, GPCRs remain 
one of the most elusive proteins to characterize because they are very difficult to study 
from expression to purification to ligand studies [17]. Because discovering new ligands is 
challenging and characterizing cross talk is even more difficult, emerging protein 
therapeutics seek to create a range of highly specific affinity proteins against GPCRs [18].  
Currently, protein therapeutics represents one of the largest and fastest growing 
areas of pharmaceutical research. One of the primary areas of protein therapeutics is 
monoclonal antibodies (mAbs), of which there are currently 34 approved in the US or 
Europe. Indeed, mAbs have seen growing FDA approval over the past few years, and single 
drug valuations in the multi-billion dollar range [19]. Beyond therapeutic targets that may 
drive funding for much of the research, antibodies have a number of other applications in 
research and medicine. 
Traditional methods of engineering antibodies for specificity or affinity maturation 
rely heavily on having soluble targets [20]. Infecting mice [21], phage display [22], yeast 
display [23], MAD-TRAP [24], and FLI-TRAP [25] were all developed with soluble target 
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proteins in mind. Because these methods all require either surface immobilization or soluble 
expression of targets, membrane proteins would have to be detergent solubilized. 
With traditional antibody screening and production models failing to satisfy 
increasing demand, a variety of technologies to engineer antibodies against specific targets 
are in development [23]. Realizing membrane proteins as valuable targets, efforts to 
engineer antibodies against membrane proteins have adapted recent antibody design 
technologies. Yeast surface display has been used to target antibodies against detergent 
solubilized membrane proteins [2] and phage display has produced scFvs against nanodisc 
solubilized membrane proteins [26]. Lipoparticles may also be used to solubilize membrane 
proteins for antibody screening [27]. 
Emerging technologies to engineer antibodies against membrane proteins rely on 
solubilizing membrane protein targets in detergents, nanodiscs, or lipoparticles [2, 26, 27]. 
These techniques, however, are unable to control the orientation of protein targets, 
meaning that it is impossible to control whether antibodies are targeted against the 
intracellular/cytosolic or extracellular/periplasmic faces of the protein. Moreover, because 
detergents may alter the structure of the protein, it is difficult to guarantee that antibodies 
will bind to the native, in vivo folding state of the protein [7]. Development of an in vivo 
technique to target antibodies against membrane proteins would provide a means to target 
antibodies against specific parts of the protein in its physiological folding state. 
Beyond therapeutic applications, antibodies have other very important applications in 
biotechnology. Diagnostics, activity modulation, and even chaperone-assisted 
crystallography would all benefit from improved antibodies against membrane proteins [9-
11]. Such important opportunities for characterization are further improved by the ability to 
obtain large quantities of high purity membrane proteins. 
In addition to designing antibodies against membrane proteins, there is value in 
improving techniques to overexpress and purify membrane proteins. One particular group of 
membrane proteins, oligosaccharyltransferases (OSTs), have emerged as an interesting and 
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valuable target for purification. OSTs constitute the central enzyme of the N-linked 
glycosylation pathway, catalyzing the covalent bonding of a glycan molecule to an 
asparagine residue in a protein [4]. N-linked glycosylation is one of the most important 
post-translational modifications in eukaryotes, and is essential for the creation of 
therapeutic antibodies [28].  
Following the functional transfer of C. jejuni N-glycosylation machinery to E. coli 
opens new doors for protein production in E. coli [4]. Differences between eukaryotic and 
prokaryotic glycosylation pathways and OSTs highlight shortcomings in current capabilities. 
In particular, limitations such as the bacterial D/E – X1 – N – X2 – S/T consensus sequence 
compared to eukaryotic N – X – S/T, different glycans, and folding states make bacterial 
OSTs less desirable for therapeutic applications [5]. Recent efforts have sought to identify 
alternative bacterial OSTs that recognize a eukaryotic-like consensus sequence [29]. In the 
DeLisa lab, efforts to synthesize eukaryotic sugars in vivo have shown that bacterial OSTs 
may work with eukaryotic sugars [30]. Folding state requirements, however, have not been 
explored in detail. 
Shortcomings in characterization make OSTs a prime target for development of a 
scalable and robust purification strategy [3]. To date, studies have focused on a single 
enzyme and do not show a robust purification strategy to compare OSTs from different 
species [29, 31, 32]). Techniques to rapidly analyze activity of a range of OSTs in vitro 
allow selection of ideal candidates for application in production of glycosylated proteins.  
Here, a scalable and robust purification strategy strives to overcome existing shortcomings. 
Together, the abilities to target antibodies against and purify large quantities of 
membrane proteins at high purity allow membrane proteins to be characterized in ways 
previously impossible. Each problem seeks to overcome some of today’s most difficult 
questions in protein engineering [2, 6]. Indeed, even incremental advancements would be 
of great value where membrane proteins are concerned. 
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CHAPTER	  2:	  SPLIT	  BETA-­‐LACTAMASE	  PROTEIN	  
COMPLEMENTATION	  ASSAY	  FOR	  SELECTION	  OF	  ANTIBODIES	  
AGAINST	  TRANSMEMBRANE	  PROTEINS	  
Targeting antibodies against transmembrane proteins is one of the largest open 
problems in protein engineering. Difficulties in expression, unique considerations of 
orientation, and challenges of purification limit the number of techniques that may be 
applied to engineer antibodies against membrane proteins. Here, a TEM-1 β-lactamase (Bla) 
protein complementation assay (PCA) is employed to build a genetic selection system to 
detect the binding of antibodies to transmembrane proteins in vivo. Binding of antibody to 
target leads to reassembly of to Bla fragments, lending resistance to beta-lactam 
antibiotics. Membrane-anchored PCA is demonstrated to be able to select for high binding 
and produce a large dynamic range of binding and selection with the use of leucine zippers. 
Early results for single chain antibody fragments (scFvs) limited resolution discerning 
between high and non-binding members. 
BACKGROUND AND INTRODUCTION 
Protein-protein interactions play an important role in nearly every cellular process. 
Assembly of multiple gene products into a single functional complex allows cells to spatially 
localize enzyme complexes, detect specific macromolecules, and selectively transcribe DNA, 
among countless other reactions. Study of protein-protein interactions has given rise to a 
suite of techniques to select for assembly of macromolecules. With the ability to select for 
interactions, engineering of specific binding molecules like antibodies is possible. 
Because of their high specificity and affinity, antibodies have been used as 
therapeutic, diagnostic, and analytical reagents for decades [9]. However, conventional 
methods to engineer antibodies against new targets rely heavily on use of animal models 
and complicated hybridoma production techniques [21].  More recent advances have seen 
protein-protein interaction assays like surface display [23, 24], yeast 2-hybrid [33], and 
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FLI-TRAP [25] based systems applied to engineer antibodies, but even these have 
substantial limitations when applied to difficult targets like membrane proteins [2]. Here, we 
use a protein complementation assay (PCA) to select for binding [34]. 
Surface display methods rely on tethering antibody fragments in bacteria or even 
whole antibodies in yeast and capturing cells on surface-immobilized antigens or detecting 
binding of fluorescence-linked antigens using flow cytometry [24, 35]. These methods rely 
on surface immobilization or soluble expression of target proteins, making targeting 
membrane proteins problematic. Recent advances have seen yeast surface display applied 
to engineer antibodies against detergent solubilized membrane proteins [2], nanodisc 
solubilized proteins [26] and lipoparticle solubilized proteins [27]. These solubilized 
proteins, however, are difficult to prepare, may not be in their native conformations, and do 
not allow targeting against specific domains (eg. Intracellular or intercellular) of a protein 
[7].   
2-hybrid systems work by assembly of a transcription promoter with the interaction 
of two target proteins and work in bacteria and yeast. One target (bait) is fused to a protein 
that binds to an upstream activating sequence and the second (prey) is fused to an 
activating domain that recruits the RNA polymerase, where successful binding of bait to 
prey results in expression of a reporter protein [36]. 2-hybrid techniques have been applied 
to investigate membrane protein interactions, allowing structures to remain in their in vivo 
conformations [37, 38]. One downside to 2-hybrid systems is demanding precise 
localization of protein complexes near DNA, a problem in organisms with more than one 
compartment. Also, they do not necessarily provide a proportional binding strength-reporter 
signal correlation, making affinity maturation difficult [39]. While 2-hybrid systems work for 
some membrane proteins, genome scale studies have highlighted that these techniques are 
inadequate for most membrane protein targets [40]. 
Because of shortcomings in surface display and 2-hybrid methods, we have chosen a 
PCA readout for this study. PCA methods use the reassembly of two reporter fragments into 
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a single, active reporter to create a selectable phenotype. This format relies on a genetic 
fusion of two complimentary fragments to each the bait and prey molecules (two interacting 
partners, eg. antibody and antigen epitope) [41]. Strong interaction between bait and prey 
brings the reporter fragments into close proximity and reconstitutes an active enzyme, as 
shown in Figure 1A [42]. Previous efforts to engineer binding molecules against 
transmembrane targets with the use of a Bla-based PCA have relied on soluble truncations 
of the target protein [43] and a mouse dihydrofolate reducase (mDHFR) PCA has been used 
to select high binding scFvs from large libraries. With PCA methods, target proteins will be 
folded in their native, membrane-integrated conformations with minimal disruption to the 
protein’s structure [44]. PCA methods can use a variety of reporter proteins, fluorescent 
proteins and antibiotic resistance enzymes most commonly [41]. The activity of fluorescent 
proteins [45] and mDHFR [46] require folding in the cytoplasm, a feature that precludes 
extracellular/periplasmic domains as targets. Keeping extracellular domains of GPCRs in 
mind as an ultimate target, split beta-lactamase is selected as the interaction reporter [42]. 
A variation of the original interaction reporters with two soluble partners [41] 
involves replacing a soluble bait molecule with a membrane protein [44]. The interaction of 
the prey molecule with part of the membrane-integrated prey reassembles the split beta-
lactamase, lending antibiotic resistance to the bacteria. For the reporter, TEM-1 beta 
lactamse is split into two segments, alpha 1-197 and omega 198-288, as developed by 
Wehrman. To demonstrate reassembly of Bla fragments, FosLZ and JunLZ, two leucine 
zipper peptides with a very high (1nM) affinity are chosen [25, 34]. These peptides have a 
number of well characterized intermediate binding mutants and have been previously 
applied to demonstrate relationships between affinity and phenotype in other protein-
protein interaction assays [25, 34]. Antibody-antigen interactions are demonstrated with 
scFv anti-GCN4 and GCN4 respectively. This pair of interacting partners is well characterized 
within the DeLisa lab [25].  
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Building off of a design of a membrane protein folding reporter from Skretas, a 
membrane protein of unknown function, yegH is used as the membrane anchoring protein 
to which a reporter fragment is fused [47]. Successful reassembly of reporter Bla is first 
demonstrated with the use of the FosLZ and JunLZ interaction system, with FosLZ being 
fused to the N-terminus of yegH and coexpressed with the soluble JunLZ construct. 
Negative controls for binding will mirror soluble interactions, using GCN4 as a non-binding 
control and well characterized JunLZ mutants for low/intermediate binding. Replacing FosLZ 
with GCN4 and coexpressing the scFv anti-GCN4 construct demonstrates the ability of scFvs 
to act as the prey molecule and reassemble active Bla in the periplasm with a membrane 
protein bait (Figure 2A). Here, a negative binding control comes in the form of scFv D10, a 
non-specific anti-GPD antibody fragment that does not bind to GCN4 [46]. 
MATERIALS AND METHODS 
Strains	  and	  plasmids	  
A set of plasmids coding for split beta-lactamse fused to Fos and Jun gifted from the 
Blau lab [34] served as templates for split beta-lactamase leucine zipper fusions. 
Intermediate binding Fos and Jun point mutants were made through quick change PCR, 
while GCN4 was inserted in place of Jun in the fusion αBla-Jun, between EcoRI and KpnI. 
PCRs of scFv anti-GCN4 and scFv D10 (anti-GPD) were similarly ligated between EcoRI and 
KpnI to form αBla-antiGCN4 and αBla-D10. Fos-ωBla-yegH was made by replacing full 
length Beta-lactamase in pBad18CM ssDsbA-Bla-yegH, “pBadBla” (gifted by the Georgiou 
lab, (Skretas & Georgiou, 2010)). Skretas selected yegH as a membrane-integrated anchor 
for full length Bla because it expresses well, and yields a selectable phenotype. Full length 
Bla was removed from pBadBla between SacI and XbaI and a PCR of ssDsbA-Fos-ωBla was 
ligated into the same restriction sites. A signal sequence, ssDsbA, was included on the N-
terminus of membrane protein containing fusions to ensure that the protein is targeted to 
the sec machinery and inserted into the periplasmic membrane. ssDsba-GCN4-ωBla-yegH 
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and ssDsbA-GPD-ωBla-yegH were cloned between SacI and KpnI from primer overlap 
extension. GPD-yegH and ωBla-yegH were cloned via primer overlap extension inserts, 
between SacI and XbaI for ssDsbA-GPD-yegH, or SacI and KpnI for ssDsbA-ωBla-yegH. 
Cloning was conducted in strain DH5α. MC4100 was used for soluble split Bla 
experiments. Membrane-anchored split Bla experiments used Walker’s C43 strain to 
improve membrane protein expression [14]. 
The NNK library of a 3 residue span of CDR3 of the parent scFv were created as in 
[25]. Briefly, the NNK randomized residues were created with the use of primers that 
contain randomized nucleotide sequences in the range of the 3 CDR3 residues of interest 
(GFA in wild type). In NNK randomization, N represents an equimolar mixture of all four 
nucleotides and K is a mixture of G and T, together NNK exclude stop codons (TAA, TAG, or 
TGA), but permits all amino acids to be encoded [25]. PCR products were ligated into the 
puc-based plasmid from Blau between EcoRI and KpnI sites. Samples of 10 µL and 100 µL 
were plated on Kanamycin selective media to estimate library size, and pooled 1ml samples 
of transformants were frozen for later selection. From the plated samples estimating library 
size, colonies were selected and sequenced to estimate library diversity. 
Determination	  of	  protein-­‐protein	  interaction	  in	  vivo	  
To determine interaction of split-Bla fused to leucine zippers, freshly transformed E. 
coli MC4100 were grown in 2 ml LB with 100 µg/ml kanamycin and 20 µg/ml 
chloramphenicol overnight. Cells were collected in the morning and normalized to the lowest 
OD. A series of 10 fold dilutions were made from 100 to 10-5 and 5µl of each dilution spotted 
onto plates containing 100 µg/ml kanamycin and 20 µg/ml chloramphenicol and a range of 
concentrations of ampicillin between 0 and 100 µg/ml were supplemented. Plates were 
grown at 30°C overnight, then at 22°C until the control (0 µg/ml ampicillin) plate grows to 
the 10-5 dilution. 
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Plasmids containing membrane-anchored split-Bla constructs were transformed into 
C43 cells plated on LB agar containing 100 µg/ml kanamycin and 20 µg/ml chloramphenicol. 
Fresh transformats were grown overnight in 2ml LB with 100 µg/ml kanamycin and 20 
µg/ml to saturation. 5ml cultures of LB with 100 µg/ml kanamycin and 20 µg/ml were sub 
cultured to an OD600 of 0.1 and incubated at 37°C for roughly 4 hours. Once cultures 
reached OD600 0.5-0.7, protein production was induced with 0.1% arabinose and cultures 
were incubated at 30°C.  The OD600 was monitored periodically until cell growth rate 
recovered from the addition of arabinose and returned to log growth phase (usually 4-6 
hours), cells were harvested with a 4,500x spin for 10 minutes and normalized by OD600, 
usually to the range of 0.7-1.0. As in the case of soluble split Bla, 10 fold dilutions were 
prepared and 5ul spots were plated. Selective plates were grown at 22°C for 48 hours on LB 
agar containing 100 µg/ml kanamycin and 20 µg/ml and varying concentrations of 
ampicillin. 
RESULTS 
Interaction	  of	  solubly	  expressed	  FosLZ	  and	  JunLZ	  
To confirm that the split Bla genetic based interaction reporter demonstrates a 
proportional binding strength to antibiotic resistance phenotype, we analyzed fusions of c-
Fos and c-Jun (FosLZ and JunLZ) leucine zippers to Bla fragments alpha and omega (αBla-
JunLZ and FosLZ-ωBla. Peptide affinity was modulated with a series of point mutations to 
specific leucine residues, allowing a range of interaction strengths to be analyzed. All fusion 
proteins are expressed in the bacterial periplasm, where reassembly of Bla yields antibiotic 
resistance. Higher affinity wild type variants FosLZ and JunLZ were expected to yield the 
highest antibiotic resistance. FosLZ mutated to FosL2V and JunLZ to variants JunL3V and 
JunL4V reduce binding strength compared to wild type, and were expected to produce an 
intermediate resistance phenotype. A negative, non-binding control was made by replacing 
JunLZ with the peptide GCN4, which does not interact with FosLZ. 
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Figure 1:(A) Schematic of soluble beta-lactamse PCA. Association of the bait and prey 
molecules (green scFv and pink antigen here) brings the N-terminal bla fragment (αBla) and 
the C-terminal bla fragment (ωBla) into close proximity to reconstitute the active bla 
enzyme (in blue). In this system, reassembly of reporter enzyme beta-lactamse yields 
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resistance to ampicillin when localized properly in the bacterial periplasm.(B) Phenotypic 
selection of FosLZ-ωBla and αBla-JunLZ variants expressed in MC4100 and plated on control 
0ug/ml ampicillin (left) and selective 50µg/ml ampicillin (right). Wild type variants are the 
strongest interacting, and show growth to lower dilutions. Modified leucine knockouts 
Fos(L2V),Jun(L3V), and Jun(L4V) and non-specific GCN4 peptide show lower resistance to 
antibiotic. A spectrum of interaction strength yields a proportional response of antibiotic 
resistance, demonstrating a high dynamic range for binding strength and resistance 
phenotype.  (C) “Kill curve” of FosLZ and JunLZ variants over a range of ampicillin 
concentrations. Strong interactions (FosLZ/JunLZ and FosLZ/JunL3V) show the highest 
resistance over a range of ampicillin concentrations, with strong growth at high selective 
pressure (100ug/ml ampicillin). Weak interactions (combinations of Fos(L2V) and 
Jun(L3V)/Jun(L4V)), show intermediate levels of resistance over a range of selective 
pressures, especially at 50 µg/ml ampicillin, where there is a clear spectrum of binding and 
resistance phenotype. Non-interacting control (FosLZ/GCN4) show very poor growth, with 
no dilutions growing above 25 µ g/ml ampicillin. This interaction assay is able to 
successfully discern between binding and non-binding partners, while also providing a high 
dynamic range to discern between intermediate binding strength partners. 
 
Wild type FosLZ/JunLZ interact with an KD of 0.99 ± 0.30 nmol [48]. As expected, 
the positive interaction FosLZ/JunLZ  has an antibiotic resistance far greater than the  
negative GCN4/FosLZ, growing to a 105 greater dilution at 50 µg/ml ampicillin (Figure 1B, 
1C). In addition to being able to discriminate between binding and non-binding, 
intermediate binding point mutants show a dynamic range of interaction. Relative resistance 
of mid affinity FosLZ and JunLZ mutants (FosL2V/JunLZ, FosLZ/JunL3V, FosLZ/JunL4V) are 
in agreement with previous predictions of binding strength (Figure 1B) [25]. Though not 
characterized in this work, one well characterized Jun mutant Jun(V36E) has an affinity of 
0.90 ± 0.13 µM [49]. FosL2V/JunL3V is observed to have a significantly weaker resistance 
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compared to FosL2V/JunlZ, while still between high and non-binding controls, satisfying 
expectations set in Waraho. Also as predicted, combinations of mutants (FosL2V/JunL3V, 
FosL2V/JunL4V) have lower resistance than mutants paired with wild type zippers.  
The kill curve in Figure 1C illustrates the spectrum of resistance across several levels 
of selective pressure for soluble FosLZ/JunLZ fused split Bla. Strong correlation of predicted 
binding strength to resistance phenotype is evident in the 25 µg/ml and 50 µg/ml ampicillin 
pressures, with differences between the groups spaced out over several orders of 
magnitude of resistance. With an estimated difference of nearly three orders of magnitude 
in binding strength between wild type and mid-binding mutants [48], a quantitative 
correlation to resistance phenotype is observed. With dilution differences of 10-2, 10-3, and 
10-4 for pairings FosLZ/JunL4V, FosL2V/JunLZ, FosLZ/JunL3V respectively, a strong 
correlation of binding strength and resistance phenotype is demonstrated. 
Membrane-­‐anchored	  Leucine	  Zippers	  
Fusing the model membrane protein yegH [47] to the C-terminus of FosLZ-ωBla 
anchors the FosLZ-ωBla fusion to the perisplasmic face of the inner membrane.  This fusion 
serves to model a binding region of the membrane protein of interest and serves to 
demonstrate that 1) reassembly of Bla anchored to the membrane is functional and 2) 
preservation of the correlation between binding affinity and antibiotic resistance phenotype.  
The same JunLZ mutant used to demonstrate affinity-resistance relationship in 
soluble split Bla is applied to the membrane-anchored split Bla. As shown in Figure 2B, the 
high binding FosLZ-yegH/JunLZ grows to high dilutions (10-6) well, even at relatively high, 
100 µg/ml, antibiotic concentrations. Mid-binding (FosLZ-yegH/Jun(L3V)) and non-binding 
(FosLZ-yegH/GCN4) illustrate range of the binding-resistance phenotype relationship. 
The high dynamic range of 103 dilutions resistance between groups holds promise for 
engineering improved binding of target molecules. High background noise in the form of 
relative resistance of non-binding cases shown in growth at 10-3 at 50 µg/ml membrane 
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linked compared to 10-1 µg/ml for soluble split Bla means that higher selective pressures, 
100 µg/ml and up, are needed to discern between high- and non-binding cases. Selective 
pressures are increased to very high levels, 500 µg/ml (Figure 2B) to illustrate that the 
phenotype is a result of binding and not a false positive due to a recombination event, which 
would yield high levels of resistance up to 1,000 µg/ml ampicillin. Poor growth for positive 
binding cases (10-3 dilution) and non/mid-binding cases (10-1 dilution) suggest that 
resistance is due to binding assembly. 
Membrane-­‐anchored	  scFvs-­‐Antigen	  Pairs	  
JunLZ is replaced with scFv anti-GCN4 (αGCN4) or scFv D10 to form αBla-αGCN4 and 
αBla-D10, while FosLZ in Fos-ωBla-yegH is replaced with the corresponding antigens GCN4 
or GPD to form GCN4-ωBla-yegH and GPD-ωBla-yegH. Antibody fragment-αBla fusions are 
coexpressed with each of the membrane-anchored antigens and plated on selective media. 
GCN4-ωBla-yegH with αBla-αGCN4 and GPD-ωBla-yegH with αBla-D10 represent positive 
interacting partners, while non-specific scFv pairings GCN4-ωBla-yegH with αBla-D10 and 
GPD-ωBla-yegH with αBla-αGCN4. Pairing of membrane-anchored antigens with a non-
interacting, non-scFv peptide αBla-JunLZ controls for spontaneous reassembly of Bla 
fragments. Further controls include GPD-yegH, lacking the ωBla fragment and offering no 
antibiotic resistance, controlling for intrinisic antibiotic resistance, while GPD-yegH lacks an 
antigen and controls for non-specific scFv binding. 
Shown in Figure 2C, pairing of specific scFvs with their corresponding antigens  
(GCN4-ωBla-yegH with αBla-αGCN4 and GPD-ωBla-yegH with αBla-D10) yields antibiotic 
resistance. However, non-specific pairings (GCN4-ωBla-yegH with αBla-D10 and GPD-ωBla-
yegH with αBla-αGCN4) also grow to high antibiotic concentrations, with a resolution of only 
102. GPD-ωBla-yegH tends to grow at higher antibiotic concentrations than GCN4-ωBla-
yegH (10-6 for GPD vs 10-3 for GCN4 at 50 µg/ml ampicillin) regardless of scFv pairing. To 
determine whether this growth is due to inherent resistance or spontaneous reassembly of 
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Bla, a negative control for each is employed. The extent of growth on negative controls 
lacking both Bla fragments (GCN4-yegH with αBla-αGCN4 and GPD-yegH with αBla-D10) 
will show the inherent resistance of cells not harboring a complete copy of Bla. Non-binding 
control ωBla-yegH/αD10 growth shows to what extent reassembly of beta-lactamse is 
occurring in a binding-independent mechanism. 
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Figure 2: (A) Schematic of membrane-anchored split Bla setup.  FosLZ-ωBla is fused to the 
N-terminus of a membrane protein to form FosLZ-ωBla-yegH, while the complimentary 
αBla-JunLZ is expressed solubly in the periplasm. Binding of FosLZ to JunLZ reassembles 
Bla anchored to the periplasmic face of the inner membrane and results in antibiotic 
resistance. (B) Kill curve of membrane-anchored split Bla with leucine zippers. As in the 
case of soluble split Bla, it is expected that high affinity wild-type partners yield higher 
antibiotic resistance. FosLZ-ωBla-yegH paired with αBla-JunLZ produces resistances on par 
with that of soluble split bla, while the non-binding αBla-GCN4/FosLZ-ωBla-yegH exhibits 
minimal resistance. Intermediate affinity Jun(L3V) lends resistance above non-binding and 
lower than high binding variants, demonstrating a high dynamic range of selection. (C) Kill 
curve of membrane-anchored split bla and scFv-antigen pairs. Two sets of scFv-antigen 
pairs are used: GCN4-ωBla-yegH with αBla-αGCN4 and GPD-ωBla-yegH with αBla-D10. 
Negative controls are formed by pairing with a non-specific scFv, substituting scFv αGCN4 or 
D10 for one another, as well as JunLZ as a non-specific peptide. In both cases, correct 
pairing (GCN4-ωBla-yegH with αBla-αGCN4 and GPD-ωBla-yegH with αBla-D10) offer the 
highest level of resistance compared to non-specific scFv (GCN4-ωBla-yegH with αBla-D10 
and GPD-ωBla-yegH with αBla-αGCN4) and non-specific peptide (GCN4-ωBla-yegH with 
αBla-JunLZ and GPD-ωBla-yegH with αBla-JunLZ). Resolution between specific and non-
specific scFv pairings is only a dilution of 102, and non-specific peptide αBla-JunLZ behaves 
similarly to αBla-D10 in both cases.  
Discussion 
Split beta-lactamase offers a selection platform for protein-protein interactions that 
is suitable for a variety of interactions and targets. Its ability to correlate resistance 
phenotype with binding strength proves valuable for improving binding of partner 
molecules, and obviates the issue of signal amplification in 2-hybrid systems [39]. 
Fragments with nanomolar affinities result in very strong growth, and a range of previously 
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characterized mutants [25] demonstrate a clear correlation between binding strength and 
antibiotic resistance phenotype. Capabilities of split Bla may be in the same range as FLI-
TRAP, which has already been applied to select and mature antibodies [25]. 
Anchoring one binding fragment to the inner membrane does not inhibit reassembly 
of active beta-lactamase. Antibiotic resistances observed are in the same range as those of 
the soluble split Bla and the binding strength-antibiotic resistance phenotype correlation is 
preserved. Enhanced binding can be selected for because of the binding-strength resistance 
phenotype correlation present in both soluble and membrane-anchored formats, offering 
advantages over n-hybrid systems. Moreover, in allowing selection of binding to natively 
folded membrane proteins, the Bla-based PCA offers advantages over yeast surface display 
methods that rely on detergent solubilized targets [2]. In allowing binding strength-
resistance phenotype correlation and natively folded structures, split Bla offers the ability to 
engineer antibodies against difficult membrane protein targets. 
Non-binding reassembly of Bla or inherent resistance of C43 cells lends a high level 
of antibiotic resistance to non-binding scFv controls in the case of membrane-anchored 
antigens. In the event of non-binding reassembly of Bla, linking sequences between binding 
domains and Bla fragments can be altered to make spontaneous assembly more difficult. 
Inherent resistance of C43 cells under selection conditions demonstrated through non-
assembling controls must be remediated by increasing resistance of the positive binding 
antibody-antigen pairs. Resistance of positive binding groups can be increased by tuning 
expression levels of antibodies and membrane-linked antigens, altering linker sequences, or 
selecting a different reporter. 
At present, antibody-antigen pairs fail to discern between high and low binding pairs 
at a sufficiently high resolution. It is unclear why membrane-anchored GPD (GPD-ωBla-
yegH) outperforms membrane-anchored GCN4 (GCN4-ωBla-yegH) under all conditions, it 
may be due to differences in expression level or reduced cell stress. The low dynamic range 
for each membrane-anchored antigen under these conditions does not allow enough 
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difference between binding and non-binding to allow for affinity maturation. For the NNK 
library, a resolution O(104) is necessary, while the full random library would be best under 
conditions that offer even higher resolutions O(106), the current O(102) resolution is 
insufficient for use with these libraries.   
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CHAPTER	  3:	  EXPRESSION,	  PURIFICATION,	  AND	  IN	  VITRO	  
CHARACTERIZATION	  OF	  OLIGOSACCHARYLTRANSFERASES	  IN	  
ESCHERICHIA	  COLI	  
Oligosaccharyltransferases (OSTs) are the core enzyme in asparagine-linked (N-
linked) glycosylation, an essential process responsible for protein targeting and function in 
eukaryotes. OSTs function by covalently linking a glycan to an asparagine residue in a 
protein substrate. Originally thought to be exclusive to archaea and eukarya, discovery and 
functional transfer to E. coli of the Campylobacter N-linked glycosylation locus has opened 
doors for application of glycosylation in bacterial expression platforms. Characterization of 
these proteins is essential to application in biotechnology. Here, a range of OSTs are 
purified and characterized for substrate sequence and folding state specificity and activity in 
vitro. OSTs from C. jejuni, and Desulfovibrio vulgaris represent two bacterial OSTs. The 
Leishmania major STT3A is the first report of a eukaryotic OST being purified and 
functioning in vitro. 
BACKGROUND AND INTRODUCTION 
An important feature in protein folding, targeting, and cell-cell signaling, N-linked 
glycosylation is an essential process in eukaryotes. This post-translational modification is of 
key interest in biotechnology and medicine, particularly with regard to production of human-
like proteins in bacteria [5]. Recent discovery of N-linked glycosylation machinery in 
bacteria and its functional transfer to the model organism E. coli has enabled the study and 
application of N-linked glycosylation in ways unattainable in eukaryotic systems [4]. In all 
domains of life, N-linked glycosylation follows the same reaction scheme where a glycan is 
assembled on a lipid carrier and then transferred to a target protein [5]. The central 
reaction where a glycan is moved from a lipid carrier onto the asparagine residue is 
catalyzed by the OST.  Characterization of this enzyme is central to the understanding and 
application of N-linked glycosylation [4, 31]. 
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Modification of an asparagine residue occurs in context of a N-X-(S/T) motif in 
Eukaryotes and Archeae and in an expanded (D/E)-X1-N-X2-(S/T) in some bacteria, where X 
is any amino acid other than proline (Eichler, 2013). The consensus sequence is necessary, 
but insufficient alone, to ensure glycosylation [50]. While there have been efforts to 
characterize the precise sequon requirements, separation of steric context and sequence 
identity can be difficult. Most eukaryotic glycosylation is performed cotranslocationally as 
the peptide chain passes through the sec translocon in the endoplasmic reticulum [51], and 
bacterial glyscosylation has been shown to occur post-translationally [52, 53]. Evidence 
from mammalian systems hints at two separate OST variants, where one glycosylates the 
unstructured N-terminus of a translating nascent protein chain and the second appears to 
modify the chain passing through the sec-translocon [54]. OSTs from the Campylobacter 
genus appear glycosylate both post-translocationally on substrates like AcrA in vitro [55] 
and co-translationally in vivo [52]. Peptide substrates offer a steric context-free method to 
evaluate OST activity on target sequons [56].  A mostly unstructured glycosylation domain 
attached to a soluble anchor protein [30] offers a means to measure glycosylation activity 
on weakly structured domains intended emulate a translocating nascent chain in vitro, and 
structured AcrA allows evaluation of glycosylation of fully folded substrates [32, 52]. 
With the publication of the crystal structure of PglB from Campylobacter lari, a 
detailed structural knowledge of C. jejuni PglB and its interaction with peptide substrates 
are well characterized [31]. Further studies have shown the role of the -2 D/E is necessary 
for binding of the peptide substrate [56].  Other bacterial OSTs, however, remain poorly 
characterized.  Recent in vivo evidence from the DeLisa laboratory suggests that certain 
OSTs from the Desulfovibrio genus may not require the acidic D/E in the -2 position of the 
sequon [29].  To examine the OST outside of context of the glycan assembly pathway and 
in the absence of steric hindrance of the peptide substrate, the OST is purified and 
characterized in vitro. Additionally, in vitro reaction allows precise control of peptide and 
LLO substrates in ways not possible in vivo [55]. 
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Beyond bacterial OSTs, eukaryotic OSTs offer a number of valuable features, 
primarily focused on compatibility with eukaryotic substrates and glycans [5]. However, 
these OSTs are likely incompatible with bacterial expression systems and translocation 
machinery necessary for cotranslocational glycosylation [57, 58]. Moreover, the majority of 
eukaryotic OSTs function within the context of an OST complex, which is responsible for 
keeping the translocating nascent protein chain unfolded and accessible while it is 
glycosylated [59]. In addition to requirements of the protein substrate, the limitations of 
LLO substrates are not fully understood [60]. Evidence has indicated that a group of STT3 
catalytic core subunits from Leishmania major are able to functionally replace the OST 
complex in Saccharomyces cerevisae [61].  Very little is known about the function of these 
STT3 catalytic core subunits, and bacteria represent a context-free platform to study these 
valuable enzymes. 
Evidence from in vivo and in vitro experiments has contributed to a detailed 
understanding of C. jejuni and C. lari sequence requirements, as well as a rough 
understanding of steric context requirements [52, 56, 58, 62]. Detailed investigation of 
folding context requires substrates to model each of three folding states: highly structured 
folded protein, loosely structured nascent chain-like substrates, and unstructured, 
unhindered domains. Highly structured protein comes in the form of AcrA, a native 
substrate of C. jejuni PglB, which folds into a coherent structure that can be purified and 
used as a substrate in vitro [32, 55]. Loosely structured regions can be attached to a 
soluble anchor protein like scFv13-R4, approximating a translating nascent chain [52]. 
Finally, fluorescently labeled peptides offer minimal structure and allow investigation of pure 
sequence requirements in the absence of steric hindrance [55, 56]. 
While the C. jejuni PglB-peptide substrate interactions are well characterized, lipid 
liked oligosaccharide (LLO)-PglB interactions are only emerging as topic of investigation [31, 
55, 56]. A rapid in vitro method to characterize OST activity opens new doors for high-
throughput evaluation of reaction conditions and allows for artificially high concentrations of 
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LLOs not possible in vivo [55]. Previous studies have looked at the specificity of C. jejuni pgl 
pathway for polyisoprenoid specificity [50], but used membrane extracts rather than 
purified OSTs. More recent studies have used purified PglB, but investigations have focused 
on C. jejuni-like LLOs [32, 55]. Ideally, eukaryotic-like LLOs would be used to add 
therapeutically desirable sugars to proteins [30] without complicated purification and in 
vitro glycan elaboration [63]. 
MATERIALS AND METHODS 
Membrane	  protein	  expression	  
OSTs with a 10x His-tag are cloned into pSN18 [62] and transformed into C43 cells. 
An overnight cultures were subcultured 1:500 into 2L of LB in a 4L Erlenmeyer flask and 
grown at 37°C until OD600 reached 0.5-0.7, then incubated at 16°C and, after a brief 
temperature equilibration, induced with 0.1% arabinose. Cells were grown overnight (16-18 
hours) and harvested at 10,000xg for 10 minutes.  
Harvested cells were resuspended in 60ml resuspension buffer (50mM tris, 1mM 
EDTA), and lysed with 3 passes in an Avastin microfluidizer at 10,000psi [64]. Unlysed cells 
were collected with a 10,000xg spin for 10 minutes. Cleared lysate supernatant was spun at 
140,000g in a Beckman SW28 rotor for 90 minutes to pellet the membrane fraction.  
Membrane fraction pellets were resuspended in 10ml solubilization buffer (20mM, 1mM 
EDTA, 100mM NaCl, 1% cymal-7 W/V) and agitated at 4°C for 2 hours before a 10,000xg 
spin for 10 minutes. The resulting pellet was the insolubile membrane fraction and the 
supernatant was the solubilized membrane fraction. 
Membrane	  protein	  purification	  
Purification methods are adapted from [32, 64]. Solubilized membrane fractions 
were mixed 1:1 with 10ml binding buffer (20mM tris, 300mM NaCl, 50mM imidazole, 0.1% 
cymal-7 W/V) to dilute EDTA in the solubilization buffer before being run over a nickel 
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immobilized metal affinity chromatography (IMAC) column. Purification was performed on a 
GE AKTA10 (GE Healthcare) using a 1ml Hi-Trap IMAC column (GE Healthcare) at 4°C, 
unless otherwise noted.  20ml of diluted membrane fraction mixture was flowed over the 
IMAC column at a rate of 0.5 ml/min, followed by a rinse with 6ml of rinsing buffer (20mM 
tris, 300mM NaCl, 100mM imidazole (Sigma), 0.1% cymal-7 W/V (Anatrace)) at 0.5 ml/min. 
Purified proteins were eluted in 5ml elution buffer (20mM tris, 300mM NaCl, 275mM 
imidazole, 0.1% cymal-7 W/V) at 0.5 ml/min.  Elution fractions were desalted into storage 
buffer (50mM tris, 150mM NaCl, 0.05% cymal-7 W/V) with 2-5 ml GE HiTrap columns at a 
flowrate of 5 ml/min. Desalted samples were concentrated above a 3kDa mass cutoff spin 
column to a target concentration of 2.0 mg/mL (Amicron Ultra). Protein concentrations were 
measured using a bicinchronic acid (BCA) assay (sigma). The BCA assay was chosen in 
preference to the Bradford because BCA is compatible with cymal-7. For storing samples in 
excess of 2 days, 10% glycerol is added to the final concentrated sample. Final samples are 
stored at 4°C. 
LLO	  extraction	  
LLO extraction was adapted from [32]. Briefly, E. coli SCM6 cells transformed with 
pACYC-pglΔB were grown to saturation overnight. Cells were sub-cultured at 1:500 into 2L 
of LB in a 4L flask and grown at 30°C for 18 hours. Cells were centrifuged at 10,000g for 
10min at 4°C and the pellets lyophilized to dryness at high vacuum overnight. All 
subsequent steps are conducted at room temperature unless otherwise noted, and with 
PTFE or glass tubes and pipettes. Lyophilized pellets were resuspended in 30ml of 10:20:3 
CHCl3:MeOH:H2O and spun for 30min at 3,000g. The supernatant was collected and any 
remaining pellet residue removed after settling in a separatory funnel. The chloroform and 
methanol from the upper phase in the separatory funnel was collected and then evaporated 
in a rotary evaporator (Buchi) at 37°C until the resulting sample was a vicious yellow liquid. 
Trace solvent was evaporated in a vacufuge for several (8+) hours (Thermo) and the 
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resulting residue was lyophilized to dryness at high vacuum overnight. The lyophilized 
powder was weighted, then resuspended in reaction buffer (10mM HEPES (4-(2-
hydroxylethyl)-1-piperazineethanesufonic acid), pH 7.5, 1mM MnCl2, 0.1% cymal-7 W/V) to 
a concentration of 0.12g/ml. Further dilutions before conducting reactions are performed in 
reaction buffer. 
 In the case of S. cerevisiae LLOs, cells from a 40L fermentation were collected and 
washed three times in PBS between spins at 300g for 5 min. About 10g cell paste was 
resuspended in 20 ml methanol and cells are lysed on a microfluidizer (Avestin) with three 
passes at 16,000 psi. Methanol was evaporated and the preparation proceeded as in the 
prokaryotic case after the first lyophylization step. 
in	  vitro	  glycosylation	  reactions	  
Glycosylation reactions of purified acceptor proteins (PglB or R4-GT) were conducted 
in 50 µl volumes with 2 µg purified PglB, 1 µl of extracted LLOs (48 µg/ml) and 5µg of 
purified acceptor protein. Reactions were incubated for 12 hours at 30°C then heated to 
95°C for 20 min to denature all proteins. 50 µl of 2x SDS PAGE loading buffer was added 
and samples were boiled for 20 min before loading 20 µl on a 10% SDS PAGE gel (Biorad) 
and run at 140V for 65 minutes. Gels were transferred to an immobilon-P PVDF membrane 
at 0.08 A per gel for 60 minutes. Transferred membranes were blocked in 5% non-fat milk 
for at least 1 hour before being probed with appropriate antibodies. 
Peptide substrates were purchased from Thermo-Fisher peptide synthesis and were 
stored in PBS and frozen at -80°C until use.  Two peptides were used: tamra-N-GDQNATAF-
C and tamra-N-GAQNATAF-C. The first mimics the optimum C. jejuni PglB sequon [56], 
while the second models the eukaryotic glycosylation sequence. Reactions were conducted 
in 10 µl volumes with 1 µg purified OST, 0.2 µl of extracted LLOs (48 µg/ml) and 280 pmol 
peptide in a buffer of 10 mM HEPES, pH 7.5, 10 mM MnCl2 and 0.1% cymal-7 W/V. 
Reactions were run for at least 90 min at 30°C, followed by 20 min at 95°C to denature 
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OSTs. 2 µl of 6x SDS PAGE loading buffer is added and samples are boiled for 20 min. 3 µl 
of the boiled mixture is loaded on a Tricine SDS PAGE gel optimized for peptide resolution. 
Tricine SDS PAGE gels are hand cast as discussed in [65].  Gels were cast in a 
BioRad Mini-PROTEAN 3 multicast chamber (BioRad) between glass plates with a gel 
thickness of 0.5 mm. Gels had a 16% AB-6 (49.5% acrylamide and 6% bisacrylamide) and 
6M Urea resolving region and a 10% AB-3 (49.5% acrylamide and 3% bisacrylamide) 
stacking/loading region. Both resolving and stacking/loading regions have 1.0 M Tris and 
0.1% SDS W/V. Poured gels were stored in 1x gel buffer (1.0 M Tris, 0.1% SDS W/V, pH 
8.45) at 4°C for up to two weeks. Lanes were loaded with 3 µl of reaction mixture with 
loading dye, or 5 µl of BioRad Precison Plus Protein Dual Xtra standard (BioRad). Up to four 
gels were loaded in a BioRad Mini-Protean Tetra Cell (BioRad), with different anode (1.0 M 
Tris pH 8.9) and cathode buffers (1.0 M Tris, 1.0 M Tricine and 1% SDS). Using a BioRad 
PowerPac Universal Power Supply (BioRad), gels were run at at 15mA per gel for 60 
minutes to ensure even stacking, followed by 135 minutes at 120V, or longer as needed for 
peptides to migrate near the bottom of the gel. Imaging was performed on a BioRad Chemi 
Doc EX using UV transillumination of naked gels. 
RESULTS 
Expression	  of	  bacterial	  and	  eukaryotic	  OSTs	  
Functional expression of C. jejuni and C. lari PglB has been long established [4]. 
Figure 3A Lane 1 of the immunoblot shows localization of C. jejuni PglB in the membrane 
fraction of E. coli, though significant amounts appeared in the membrane insoluble (lane 2) 
and lysate (lane 3). It is expected that closely related OSTs express similarly in E. coli. This 
was true of other members of the Campylobacter species, from which C. lari PglB appears in 
the membrane fraction as high mass bands, as though aggregated in inclusion bodies or 
detergent-resistant complexes (not shown). In figure 4A, Desulfovibrio vulgaris PglB 
expression is shown compared to C. jejuni PglB. D. vulgaris was expected to express, since 
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it appears to function in vivo in E. coli (Guarino, unpublished). The D. gigas OST showed low 
levels of expression, but D. desulfuricans did not seem to express (not shown). 
Of the three L. major STT3 core enzyme variants able to supplant the S. cerevisae 
OST complex (STT3A, STT3B, and STT3D) [61], only the STT3A variant expressed in E. coli 
(Figure 4B).  As shown in lanes 1-3 of Figure 3B, L. major STT3A localized as expected to 
the membrane fraction, though significant amounts are present in detergent-resistant high 
mass aggregates and membrane insoluable fractions (Figures 3B, 4B). The other three 
variants, however, did not show strong bands in any fraction other fractions (not shown). 
Successful expression of any eukaryotic OST was unexpected, and shows promise for study 
of this interesting and valuable protein. These L. major STT3 core enzymes some of the 
closest related eukaryotic OSTs to C. jejuni PglB (Supplemental Figure 1A). 
Purification	  of	  bacterial	  and	  eukaryotic	  OSTs	  
Suitable expression level often indicators whether or not a protein can be purified. 
OSTs that do not express well do not purify in quantities large enough to be useful in vitro. 
C. jejuni PglB had previously been purified and serves as a model for development of a 
suitable in-house purification strategy [32, 64]. BCA measurements of purified proteins 
estimated yields of up to 0.8 mg/L despite only cursory optimization. Optimization of 
expression or scaling up culture strategy alone could drastically increase yield with few 
downstream changes [3]. 
Coomassie stained gels (Figure 3A left) show that the purification fractions of C. 
jejuni PglB were reasonably clean, with no major impurities within detection limits; while 
western blots (Figure 3A right) confirm that the coomassie stained bands are indeed His 
tagged PglB. PglB, like most membrane proteins, tends to accumulate in high-mass 
aggregates, and IMAC purification excluded many of the high-mass aggregates that appear 
in the lysate and membrane fractions (Figure 3A right). Desalting into storage buffer did not 
yield significant loss of protein, an example of which is shown in the last two lanes of Figure 
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3B. Purification was also effective with D. gigsas and D. vulgaris PglB, though not shown. 
These two particular Desulfovibrio OSTs had yields of 0.4-0.7 mg/L, while a third, D. 
desulfuricans did not express, nor purify (not shown). As demonstrated in the purification of 
OSTs from diverse species, the strategy developed here is robust for OSTs that express 
well. 
 
Figure 3: (A) Coomassie stain (left) and western blot (right) of Campylobacter jejuni PglB 
purification. Target PglB is abundant in high-mass aggregates and low mass degradation 
products in the membrane fraction, membrane insoluble fraction, and cleared lysate. After 
purification, PglB appears in the western blot at the expected mass (~80 kDa), and the 
coomassie shows clean fractions, though yields of PglB are below the coomassie detection 
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threshold when unconcentrated. Running at roughly 150 kDa, a potential dimer appears in 
the first successful elution fraction, it is unclear if this is an artifact of the purification 
process, or a property of PglB. A gradient of imidazole is used here to find the minimum 
elution concentration for subsequent purifications. Final yields are 0.8 mg/L (B) Coomassie 
stain (left) and western blot (right) of Leishmania major STT3A purification. Low expression 
levels in E. coli means that STT3A does not appear in lysate, membrane, or membrane 
insoluble fractions in this purification. A more concentrated membrane fraction can show 
expression of STT3A (Figure 3B). Target STT3A appears near the expected ~80 kDa mass in 
the desired elution lane (Lane 6). Relatively high imidazole concentrations and low affinity 
for the IMAC column results in an undesirable loss of target protein in the wash step (Lane 
5). The coomasie stained gel shows that fractions containing STT3A (elution and desalt in 
particular) are relatively free of impurities. The final yield of L. major STT3A is 0.4 mg/L.  
 
A portion of expressed L. major STT3A accumulated in high mass aggregates in 
membrane fractions of E. coli. In Figure 3B, IMAC purification yields proteins at the 
expected mass. Faint bands at roughly 160kDa in the coomassie gels of L. major STT3A 
purifications (Figure 3B) suggest the formation of dimers, confirming previous findings in 
yeast [61, 66]. It is unclear if these apparent dimers are active in vitro, or are artifacts of 
the preparation process, as migration of membrane proteins is highly variable with 
detergent, lipid, and Coomassie concentrations [67, 68]. Final yields were calculated to be 
0.5 mg/L. This is the first reported expression and purification of a eukaryotic OST.  
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Figure 4: (A) membrane fraction from E. coli C43 cells expressing OSTs from Campylobacter 
jejuni and Desulfovibrio vulgaris. OSTs are expected to run around 80 kDa, but significant 
high mass aggregates characteristic of membrane protein overexpression obscures clean 
bands. OSTs that do not express often do not even have high mass aggregates (not shown). 
C. jejuni expression appears the strongest and has the least degradation product, and 
consequently has the highest purification yields of any OST expressed. D. vulgaris PglB 
shows the same characteristic high mass aggregates, but also high levels of low mass 
degredation products. (B) Expression of L. major STT3 core in E. coli C43. Three variants of 
the STT3 core are expressed: A, B and D, as well as D fused to MBP. High mass aggregates 
characteristic of membrane protein overexpression appear only in the STT3A case (Lane 1), 
with no trace of other variants detected. STT3A also appears as low mass aggregation 
products, though those do not appear in the purification process (Figure 3B). Because only 
STT3A expresses in E. coli, it is selected for purification and in vitro characterization. 
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in	  vitro	  activity	  of	  bacterial	  and	  eukaryotic	  OSTs	  
To evaluate OST activity, two readouts of in vitro assays are used: immunoblot of 
purified acceptor proteins and in-gel fluorescence of peptide substrates. Here, the purified 
acceptor proteins used were either AcrA, a native substrate of C. jejuni PglB or sfFv R4 with 
four glycosylation sequon repeats fused to the C-terminus (R4-4xGT). AcrA, as a fully folded 
protein offered the highest level of steric hindrance [32, 55], while R4-4xGT has reduced 
steric hindrance to model a translocating nascent chain [45]. The scFv R4-4xGT also may be 
easily recloned with an arbitrary sequence with relatively little effort.  Here, R4-4xGT comes 
in three varities: 4xAQNAT, to mimic a eukaryotic consensus sequence, 4xDQNAT, the 
optimal Campylobacter sequence, and 4xDQAAT, a negative control which lacks the target 
asparagine residue [56, 62]. 
Peptide substrates offer high sequence flexibility for a relatively low cost, allow 
evaluation of substrate sequence requirements, and permit rapid, quantitative measure of 
glycosylation. These peptides were chemically synthesized by Thermo Fisher and have a 
longer shelf life than other purified proteins used here. Fluorescence measurements are 
highly sensitive and thus reactions were conducted in much smaller volumes than the 
immunoblot assays, meaning that highly valuable reagents (purified OSTs and LLOs) go a 
long way. Most importantly, the assays were easily made consistent and quantitative 
between independent sets of reactions. A simple standard curve illustrates that the assay 
was quantitative in ranges from O(1) pmol to O(100) pmol (supplemental Figure 1C). 
To confirm that in vitro assays used here work properly, C. jejuni plgB was evaluated 
as a model enzyme because it is already well characterized [32]. Figure 5A illustrates the 
ability of purified C. jejuni PglB to function in vitro and specifically attach glycans to AcrA at 
both native sites. The left blot illustrates the presence of acceptor AcrA, while the right is 
specific for the C. jejuni glycan. Addition of PglB to a reaction mixture resulted in 
glycosylation, shown by a commensurate mass shift in AcrA on the His blot and appearance 
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of a band on the anti-glycan blot. The mass shift and specific detection of a glycan together 
demonstrate addition of a specific glycan to the target protein. 
 
Figure 5: (A) Immunoblot glycosylation activity assay with C. jejuni PglB using purified AcrA 
as the acceptor protein. Purified AcrA and LLOs were incubated with (Lanes 2 and 4) and 
without (Lanes 1 and 3) C. jejuni PglB and the completed reactions were boiled and run on 
a 10% SDS page gel. The left membrane is probed with anti-His to show the mass shift of 
the AcrA acceptor protein and the right is probed against C. jejuni glycan to show the 
specific addition of the glycan. In the left blot, the AcrA band is shifted up approximately 
2kDa, indicating the addition of two glycans, while the right blot shows a single band in the 
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reaction containing PglB, indicating specific addition of the C. jejuni glycan to PglB. (B) 
Glycosylation activity assay conducted with L. major STT3A using purified AcrA as the 
acceptor protein. Omission of each reagent, STT3A, LLO, and AcrA, illustrates that the 
reaction progresses to completion only with all present. Successful glycosylation of a target 
is shown with a mass shift in the His blot and the appearance of a band in the glycan blot. 
AcrA is the intended protein substrate of STT3A, but does not appear in the glycan blot, and 
does not show a mass shift in lane 2 compared to other lanes on the His blot. A band 
corresponding to glycosylated STT3A appears in lanes containing STT3A and LLOs (2 and 3), 
but not in those lacking one of the reagents. There is no observed mass shift of STT3A, but 
a 0.7 kDa difference on a ~80 kDa protein cannot be detected with this type of gel. 
Appearance of a ~80 kDa band in the anti-glycan blot suggests homoglycosylation of 
STT3A. (C) Peptide glycosylation assay with L. major STT3A. Tamra labeled GDQNATAF and 
GAQNATAF peptides are incubated with STT3A and varying concentrations of LLO. At 
sufficiently high concentrations of LLO (192 µg/mL, lane 2), STT3A appears to be able to 
glycosylate both the bacterial and eukaryotic glycosylation sequences. Pink lines are drawn 
through the calculated center of each band using Image Lab software (BioRad) to highlight 
the mass shift of peptides in lane 2. 
 
Using this AcrA based assay to evaluate L. major STT3A core, it is clear that the 
enzyme does not glycosylate AcrA, shown by the absence a mass shift in the His blot and 
absence of any bands in the predicted range in the anti-glycan blot. However, the 
immunotblot shows that the L. major STT3A core was able to homoglycosylate, adding a C. 
jejuni glycan to another (or perhaps the same) STT3A molecule. In lanes 2 and 3 of Figure 
5B, appearance of a glycan specific band in the range of STT3A suggests specific 
glycosylation of STT3A. These bands are present only in cases that contain both purified 
STT3A and LLOs, and appear independent of AcrA. No mass shift is observed for STT3A in 
the anti-His blot because the percent difference in mass (2%) is not sufficient to discern in 
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this region of the gel. A search of the amino acid sequence and rough estimates of 
backbone flexibility revealed that the protein is likely glycosylated on its flexible N-terminus 
at 30NTS. The L. major STT3A core was able to be functionally expressed and purified from 
E. coli, and maintained its activity in vitro. This is the first example of a eukaryotic OST 
being expressed functionally in E. coli, and the first example of a purified eukaryotic OST 
being functional in vitro. 
Glycosylation of peptides reveals steric constraint-free sequence requirements of 
OSTs and allows simple quantification of extent of glycosylation. Figure 7a illustrates the 
ability of PglB to glycosylate peptides with DQNAT acceptor sequence but not those with 
AQNAT, confirming established findings [31, 56]. Reactions in lanes 1 and 2 were conducted 
with DQNAT, while 3 and 4 used the AQNAT acceptor sequence; together they represent a 
positive and negative control for the -2 acidic residue. Since differences in hydropathy and 
charge to mass ratio of aspartic acid and alanine significantly altered the way that the small 
peptide migrated through the gel matrix, the peptides appear as different masses in the gel, 
illustrated in comparing lanes 1 and 3 in Figure 6A. Addition of PglB to a reaction mixture 
containing LLOs and fluorescent linked GDQNATAF resulted in a portion of the peptide 
appearing at a higher mass than the PglB lacking negative control (illustrated in a higher 
mass band in lane 2, which is absent in lane 1). Figure 6D below shows the reaction’s need 
for LLOs to proceed to completion. In the case of GAQNATAF, however, no mass shift is 
observed because C. jejuni PglB is unable to glycosylate substrates lacking an acidic residue 
in the -2 position due to an inability of R331 to coordinate peptide orientation via hydrogen 
bonding (Figure 7D). This confirms previous observations regarding signal sequence 
requirements for C. jejuni PglB and illustrates the ability of this assay to discern between 
glycosylated and unglycosylated peptides. 
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Figure 6: (A) Peptide glycosylation assay for C. jejuni PglB with tamra-labeled peptides. 
Peptide substrates with bacterial DQNAT or eukaryotic AQNAT are incubated with C. jejuni 
LLOs with and without the of C. jejuni PglB. Addition of C. jejuni PglB to the reaction 
mixture results in a mass shift in the peptide coding for DQNAT, seen as a portion of the 
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peptide fluorescing at a higher mass g1. This mass shift is not observed in the case of the 
eukaryotic consensus sequence AQNAT. (B) Peptide glycosylation assay investigating the 
role of LLO concentration on C. jejuni PglB activity. Tamra-labeled GDQNATAF is incubated 
with C. jejuni PglB and range of concentrations of C. jejuni LLOs. Portion glycosylated is 
calculated as the ratio of g1 band fluorescence to total lane fluorescence. Higher 
concentrations of LLO result in more glycosylation. Because 48 µg/ml is not statistically 
significant from 96 and 240 µg/ml, it was selected as the optimal LLO concentration. (C) 
Time course of C. jejuni PglB peptide glycosylation reaction. Samples of a reaction 
containing C. jejuni PglB, C. jejuni LLOs, and tamra-labeled GDQNATAF are incubated at 
30°C, and reactions are quenched every fifteen minutes and run on a Tris-Tricine gel. 
Extent glycosylated (graph above) is calculated as ratio of g1 fluorescence to total lane 
fluorescence calculated with Image Lab (BioRad) from the fluorescence image (below). 
Reaction reaches completion in roughly 45 minutes, and subsequent time points are not 
statistically different (the 60 minute time is calculated as lower yield because the band is 
saturated). Subsequent experiments were run for 90 minutes to ensure they reach 
completion. (D) Activity of C. jejuni PglB with C. jejuni, C. lari, and S. cerevisiae LLOs. 
Tamra-labeled GDQNATAF is incubated with C. jejuni PglB and 48 µg/ml of either C. jejuni 
or C. lari LLOs. Mass shift of g0 band to g1 is caused by increased difficulty of migration 
through the matrix with the addition of a glycan. The difference in extent glycosylated 
between LLOS (eg. C. lari appears to only be about half glycosylated) cannot be attributed 
to the glycan identity, since purity and homogeneity of samples is unknown. This also offers 
the first demonstration of the glycosylation with a eukaryotic LLO extract, with LLOs 
prepared from S. cerevisiae. (E) Comparison of C. jejuni and C. lari glycans. C. jejuni 
features a branched hexose residue on the fourth sugar residue. Lipid carriers for both LLOs 
are expected to be identical. S. cerevisiae LLOs are extensively branched and contain 
different sugar residues. Like all eukaryotic LLOs, S. cerevisiae LLOs use a dolichol lipid 
carrier, unlike the bacterial undecaprenol. 
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 The LLO concentration assay (Figure 7B) was used to investigate the role of LLO 
concentration on C. jejuni PglB and to inform the optimal reaction conditions of 48µg /ml 
LLO. Increased LLO concentration correlated to an increase in extent of glycosylation. 
Calculating the ratio of fluorescence between unglycosylated and glycosylated bands allows 
direct quantification of extent of glycosylation. Error was estimated based noise per unit 
area in regions outside of bands. Here, samples 24-240 µg/ml (lanes 5-8 in Figure 6B) were 
not statistically significant from one another. 48µg is selected because the unglycosylated 
signal was not different from that in higher concentration cases, but shows a greater signal 
than lower concentrations. 
A time course experiment was conducted by quenching reactions with addition of β-
mercatoethanol, SDS, and glycerol in the form of 6x SDS loading dye and boiling samples to 
denature PglB. Calculation of vmax from data in Figure 7C suggests a substrate turnover rate 
of once every four minutes. Compared to a previously reported enzyme rate [56] and 
assuming perfect purity, the sample was 2% active, an understandable finding given that 
the enzyme preparation was roughly 6 months old at the time of the experiment. It is 
important to note that this measurement is only valuable as a relative comparison between 
enzymes and is likely different than the in vivo rate, which may rely on association with 
additional protein machinery in the cell.  
In addition to C. jejuni PglB, L. major STT3A was also able to use tamra-labeled 
peptides as a substrate. Figure 4C shows the peptide glycosylation assay applied to L. major 
STT3A. A mass shift is observed only in the case of high (192 µg/ml LLO, in lane 2) LLO 
concentrations. Peptide mass shift (difference between g0 and g1) appears smaller than 
other assays for unknown reasons, but it is suspected that it is an artifact of gel quality. The 
mass shift is not believed to be an artifact of lipid concentration because the presence of 
even higher lipid concentrations in Figure 6B shows the clear presence of bands at g0 and 
g1 glycosylation states. 
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Using LLO preparations from E. coli SCM6 cells harboring a plasmid coding for the pgl 
locus from C. lari, it is demonstrated that C. jejuni PglB is able to glycosylate a tamra-
labeled DQNAT peptide with both C. lari and C. jejuni glycans (Figure 6D). Incubating C. 
jejuni PglB with either C. jejuni or C. lari LLOs resulted in glycosylation of peptide 
substrates, shown in the mass shift from g0 to g1 of GDQNATAF peptide in Figure 6D. 
Shown in Figure 6E, the C. jejuni and C. lari LLO N-glycans differ by the presence of a 
branching hexnac residue [69]. Addition of LLOs to a reaction mixture containing peptide 
substrate and PglB results in the characteristic mass shift of the peptides for both species of 
LLO (Figure 6E). Quantitative measurements indicate that C. jejuni PglB was about twice as 
efficient with is native LLOs compared to C. lari LLOs, though the concentration of mature 
LLOs within a lipid extract sample is unknown and difficult to measure.  
LLO preparations from eukaryotic S. cerevisiae are also shown to work with C. jejuni 
PglB (Figure 6D). Recent work has shown that the C. jejuni PglB can work with dolichol 
substrates at low efficiency [55], and can use eukaryotic glycans [30]. This result combines 
the two findings into a single substrate to show relaxed specificity for lipid and 
oligosaccharide at the same time. This is the first report of C. jejuni PglB using a eukaryotic 
lipid extract as an LLO substrate. 
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Figure 7: (A) Glycoylsation of R4-4xGT with D. vulgaris PglB. Purified R4-4xGT is incubated 
with C. jejuni LLOs and with or without D. vulgaris PglB. Western blot probed against flag 
tag demonstrates even expression in each sample group, while probing against glycan 
shows specific addition of C. jejuni glycan. Addition of D. vulgaris PglB results in 
glycosylation only in the case of bacterial glycosylation sequence DQNAT. eukaryotic 
sequence AQNAT and negative control DQAAT are not glycosylated, since no band appears 
at the predicted mass of R4-4xGT. (B) Glycosylation of tamra labled bacterial GDQNATAF 
and eukaryotic GAQNATAF peptides with D. vulgaris PglB. Labeled peptides and LLOs are 
incubated with and without D. vulgaris PglB. Addition of enzyme is necessary for 
glycosylation and is expected to result in a mass shift from g0 to g1. In both cases a band 
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appears at g1. Band intensity between g0 for cases with and without PglB is not constant 
because this image is a crop of a peptide dilution series experiment. D. vulgaris PglB 
required higher peptide concentrations than C. jejuni PglB when paired with C. jejuni LLOs 
and tamra labeled peptides. (C) Sequence alignment of Campylobacter lari PglB and 
Desulfovibrio vulgaris PglB near R331 and R332. R331 and R332 are necessary for 
coordination of protein substrate and mutations in this region may have consequences for 
substrate specificity. Here, D. vulgaris PglB lacks an arginine residue in that area, leading to 
predictions of altered substrate specificity. (D) Crystal structure of Campylobacter lari PglB 
in the catalytic cleft showing the peptide substrate and residues responsible for coordinating 
its orientation. Of particular are of interest is the region around R331 and R332, which 
participates in a hydrogen bonding network that stabilizes the acidic -2 residue of the 
protein substrate. 
 
The fluorescent peptide glycosylation has also been applied to other bacterial OSTs. 
Figure 7B shows the glycosylation of DQNAT and AQNAT peptide substrates with 
Desulfovibrio vulgaris PglB. With the addition of D. vulgaris PglB to the reaction mixtures 
containing LLO and peptide substrates, a mass shift indicative of an added glycan from g0 
to g1 appeared. Recent in vivo data suggests that this enzyme has relaxed specificity for 
substrate sequences when expressed in E. coli (Guarino, unpublished). While the enzyme 
appears to operate at a low efficiency, there are a number of factors that may contribute to 
this, including LLO specificity, purity and reaction conditions. Also apparent in Figure 7B is 
the greater fluorescence intensity in lanes 2 and 4 compared to lanes 1 and 3. This is due to 
higher concentration of peptide in lanes 2 and 4, as part of an assay intended to optimize 
reaction conditions. 
The R4-4xGT fusion is intended to model the loosely structured translocating nascent 
chain. Here, only D. vulgaris has successfully been used on this substrate. In Figure 7A, an 
anti-FLAG Blot (above) shows even loading of R4-4xGT between reactions, while specific 
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probing for the C. jejuni glycan shows glycosylation of R4-4xGT. It was expected that 
DQNAT and AQNAT should be glycosylated, as in the case of peptide assays and in vivo 
evidence (Figure 7B, Guarino, unpublished). However, only R4-4xDQNAT was glycosylated, 
and shown via anti-glycan blots. It remains unclear why R4-4xAQNAT is unglycosylated 
against expectation. R4-4xAQNAT was observed to be, as expected, unglycosylated. No 
mass shift was observed in the anti-FLAG blot, perhaps due to glycans blocking access to 
the FLAG tag, meaning that glycosylated proteins do not appear in the above blot. 
DISCUSSION 
The primary advantages of characterizing OST function in vitro is that the 
concentrations of substrates and cofactors can be precisely tuned and that the enzyme 
functions independent of the glycan synthesis pathway, sec translocon and chaperones. 
These two combined features allow study of the enzyme in ways that cannot be controlled in 
vivo [56]. Moreover, the simplicity of the system allows reactions to be conducted in the 
absence of inhibiting substances and proteases, ensuring high quality and homogeneity of 
glycosylated product. Indeed, efficiency and extent of glycosylation in vitro is often higher 
than that observed in vivo [28, 56, 58]. Enzyme substrates including both LLOs and 
acceptor can be evaluated in a much higher throughput manner than in vivo, with hundreds 
of conditions easily tested in a single day. This constitutes not only a tool for rapid 
characterization, but optimization of reaction conditions. Moreover, the ability to precisely 
control both LLO and peptide substrate concentrations and measure product concentrations 
opens new doors for understanding reaction kinetics in ways otherwise inaccessible. 
Expression and purification of OSTs from an E. coli expression platform has proven 
successful for targets from a range of species. Well understood C. jejuni (Figure 3A) and C. 
lari (not shown) PglB were used to optimize expression and purification methods, before 
scaling to other well expressed bacterial OSTs, like D. vulgaris. Techniques that were 
successful for bacterial OSTs were applied to L. major STT3A, the first eukaryotic OST to be 
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expressed and purified from E. coli. Activity assays in vitro confirm function of C. jejuni and 
D. vulgaris OSTs with a selection of target sequences and steric constraints. Experiments 
with purified AcrA and peptide substrates and L. major STT3A represent the first reported in 
vitro activity of a eukaryotic OST. Of the OSTs expressed and purified, the L. major STT3A 
is the most distant evolutionarily from any other target, suggesting that the technique 
should be robust for this class of protein. 
The previously established requirement of C. jejuni PglB substrates to possess the 
canonical bacterial glycosylation sequence (D/E)-X1-N-X2-(S/T) (where X1 and X2 are any 
amino acid except proline) is confirmed by both the immunoblot and peptide based assays 
using DQNAT and AQNAT sequences. D. vulgaris PglB seems to have a preference for the 
bacterial DQNAT using the R4-GT substrate and no preference for peptide substrates. This 
may be due to steric constraints in the catalytic cleft of the enzyme. An alignment of 
sequences around the R331 (Figure 7C), the residue important for substrate coordination in 
C. jejuni (Figure 7D) shows differences in sequence that may explain relaxed substrate 
specificity and steric constraints.  
Immunoblot assays show that L. major STT3A is able to homoglycosylate, but is 
unable to glycosylate fully folded AcrA. These observations, given previous findings of 
eukaryotic and mammalian OSTs are not expected to be able to glycosylate structured 
domains [51, 54]. Sequence analysis reveals a probable glycosylation site on the highly 
flexible N-terminus residues 30NTS. Observations of L. major STT3A activity with peptide 
substrates confirms expectations that STT3A is able to glycosylate the minimal eukaryotic 
sequon of N-X-T in unstructured substrates. L. major seems to require high concentrations 
of LLO for function, and does not produce as large a mass shift as other experiments. The 
lower mass shift may be due to a preference for rare, unelaborated glycans that more 
resemble eukaryotic glycans. Use of eukaryotic OSTs in bacteria holds promise for extensive 
applications in biotechnology. 
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With the ability to purify and characterize a diverse set of OSTs in a robust and 
scalable way new insight about these valuable proteins can be gained rapidly. 
Characterization of each enzyme’s preference for sequon identity and steric requirements 
permits identification of ideal candidates for applications protein production. The ultimate 
goal will be to identify enzymes that are able to glycosylate eukaryotic acceptor sites on 
sterically constrained peptide substrates, allowing for the most diverse range of acceptor 
proteins. Enzymes that perform as desired could then be engineered for improved 
expression and find application in large scale protein production.  
Differing specificities for sequence and lipid carrier can be leveraged to select a set of 
enzymes that is able to place different glycans on unique sites with high specificity. In 
eukaryotic systems, elaboration and completion of the glycan occurs after translation and 
translocation, requiring a range of enzymes that may not be an option in an E. coli host [5, 
30]. Such specificity will allow for glycan diversity far beyond current capabilities, and open 
doors for production new and interesting proteins that are currently difficult targets, 
including proteins from arcaea. 
The high throughput nature and quantitative output of the in-gel peptide 
fluorescence assay allow for measurements that are otherwise difficult with immunoblot 
assay, including the role of LLO concentration and kinetic rates. To date, Michaelis Mentin 
kinetics have been used to model OST activity [56], an assumption that requires fixed 
concentration of either LLO or protein substrates. A more accurate ternary-complex model 
can be applied to better understand the kinetics of substrate binding and reaction 
mechanism. Details like substrate binding order and release order can be explored in ways 
previously not possible. Understanding of these mechanisms can be used to optimize both in 
vivo and in vitro systems and provide guidance for further optimizations. 
Previous studies have shown flexibility of C. jejuni PglB with truncated glycans and 
varying lipid substrates [30, 50, 55], but this is the first demonstration with fully exogenous 
glycans. Other results have confirmed that this enzyme is able to function with diverse 
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glycans, including eukaryotic-like substrates [30]. Emerging techniques to synthesize other 
interesting glycans [55, 70] may allow in vitro glycosylation with sugars that are otherwise 
difficult to synethsize in vivo. Intersting sugars, particularly azido-sugars, can be used to 
functionally label proteins in specific locations with high efficiency and minimal impact to a 
protein’s structure. The demonstration of function with S. cerevisiae LLOs opens doors to 
use lipid extracts from valuable sources. Previously established relaxed specificity for 
glycans [50,55] and glycans [30] invited the idea of using mixed glycans that may be 
valuable in biotechnology. S. cerevisiae serves as a proof of concept and more complex 
substrates may be possible. 
Evaluation of substrate requirements for protein substrates and homology modeling 
of the catalytic core to the C. lari structure may lend insights into how different OSTs 
interact with their substrates. Understanding protein-OST interactions can allow engineering 
of bacterial OSTs that will glycosylate eukaryotic substrates. It may also be the case that 
folding state and acceptor sequences are closely related features, where the acidic -2 
residue coordinates fully folded proteins, performing the job of the chaperones that unfold 
and coordinate protein substrates [56]. In presenting substrates with a variety of different 
folding states, levels of steric hindrance, and amino acid sequence, this work allows 
answering of questions that have previously evaded researchers.  
Application of these purification and characterization techniques to a broad range of 
OSTs will lead to an enhanced understanding of one of the most important post-
translational modifications. Improved understanding may even lend insight into diseases 
caused by malfunction of glycosylation machinery [71]. With enhanced fundamental 
understanding, and a means to produce large, high purity quantities of OSTs, additional 
crystal structures are within reach. With a number of parallel advances in glycan design and 
LLO production, eukaryotic therapeutic proteins will be accessible targets for production 
using E. coli as a platform. 
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CHAPTER	  4:	  NOTABLE	  ACHIEVEMENTS	  
First demonstration of beta-lactamase based reporter for interaction between soluble and 
membrane proteins capable of genetic selection 
Demonstration of high dynamic range for strong associating peptides between soluble and 
membrane proteins 
Development of a scheme to engineer antibodies exclusively against 
periplasmic/extracellular domains of membrane proteins 
  
 
First example of eukaryotic oligosaccharyltransferase expression in E. coli 
First example of eukaryotic oligosaccharyltransferase purification from E. coli 
First example of eukaryotic oligosaccharyltransferase activity in vitro 
First use of yeast membrane extracts as an LLO substrate for C. jejuni PglB 
Evaluation of a diverse selection of oligosaccharyltranferases with peptide substrates to 
examine substrate sequence specificity 
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CHAPTER	  5:	  FUTURE	  DIRECTIONS	  
 
Split Beta-Lactamase Protein Complementation Assay for Selection of 
Antibodies Against Transmembrane Proteins 
The ultimate goal of engineering antibodies against an arbitrary membrane protein 
target requires three intermediate goals. First, selection conditions that offer an appropriate 
dynamic range between binding and non-binding cases must be found. Second, scFv 
libraries must be selected against a contrived target using the new selection conditions. 
Finally, binding of antibodies is to be confirmed in vitro to ensure that observed resistance is 
not an artifact of a non-specific binding interaction. These three aims together yield a 
methodology that enables the targeting of scFvs against arbitrary transmembrane protein 
targets. 
Specific	  Aim	  1:	  Optimizing	  Positive-­‐Negative	  Signal	  Resolution	  for	  scFv-­‐antigen	  
interactions	  
Having demonstrated the ability of split membrane-anchored beta-lactamase to 
confer antibiotic resistance correlated to fragment binding strength, a platform for 
engineering binding molecules is ready for application. Presently, scFv based binding 
systems are not sufficiently orthogonal to give rise to conditions that allow selection of 
appropriately large libraries (Figure 2C). Current shortcomings may be due to spontaneous 
reassembly or inherent resistance, as demonstrated with the non-binding and inherent 
resistance controls. Inherent resistance is overcome by increasing the positive binding cases 
and non-binding assembly is remediated by increasing the barrier of interaction for reporter 
fragments. 
Optimization is necessary to find conditions that allow appropriate selection 
resolution, by either increasing positive case resistance or decreasing non-binding 
interaction of reporter molecules. Here, optimization in either case relies on tuning two 
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facets of the system: bait/prey configuration and expression level. Should these methods 
fail, alternative scFv frameworks and reporters can be explored. Reporter configuration is 
altered by changing the order of fusion proteins, and identity of reporter-fusion pairs. 
Expression level is tuned by exploring alternative expression platforms and assay 
conditions. Lastly, alternative scFv frameworks and reporters can be considered. 
Sub	  aim	  A:	  Altering	  Bait/Prey	  Configuration	  
It has been shown that the order of bait and prey in reference to reporter fusion (N-
terminal reporter vs C-terminal reporter) and the identity of the reporter fragment can 
influence the effectiveness of reporter assembly [44]. To explore these configurations, 
constructs will be recloned replacing the reporter fragment and/or changing the order of 
reporter and bait/prey. This reconfiguration is accomplished with simple directional cloning 
into the already modular vector. Testing of new combinations is accomplished by applying 
the proven plating selection methods, and will use the already proven controls to 
demonstrate effectiveness. 
For example, current cases rely on N-antigen-ωBla-membrane protein-C and N-scFv-
αBla-C as the bait and prey respectively. Altering the prey configuration to N-αBla-scFv-N, 
or bait and prey to N-αBla-antigen-membrane protein-C and N-scFv-ωBla-C may offer 
greater resolution between binding and non-binding cases by reducing spontaneous 
assembly of reporter fragments. By making assembly slower or more difficult, the 
background noise is reduced and signal to noise ratio of positive cases is increased. 
Sub	  Aim	  B:	  Tuning	  expression	  level	  
Expression levels of associating fragments is a key aspect of optimizing PCA methods 
[42]. Given proven sensitivity to expression level, the membrane-anchored component is 
the more difficult of the two constructs to alter. Thus, relative expression is best tuned by 
recloning the scFv portion into a vector under the control of a highly tunable promoter. This 
will allow the relative concentrations of bait and prey to be tuned over a much wider range 
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than the current puc-based expression platform [34]. With this, it will be possible to explore 
the stoichiometry of the antibody-antigen interaction and offer new directions to optimize 
this particular selection platform. 
Current options for a scFv-reporter fusion plasmid are only limited by bacterial 
resistance. The chloramphenicol resistant pBad-18 that forms the backbone of the yegH 
expressing plasmid and the ampicillin resistance of the binding reporter exclude those two 
antibiotics from the new plasmid’s resistance. Viable options for such a plasmid include a 
Kan resistant pET vector (high expression) or Kan resistant tetracycline inducible (highly 
tunable expression) vector. 
Sub	  Aim	  C:	  Framework	  matching	  
Changes to scFv framework can have dramatic consequences for expression level 
and folding stability [24]. The current configuration using D10 and scFv anti-GCN4 
frameworks may create irreconcilable differences in expression level. Selecting controls 
made from the same scFv framework should balance expression levels and more accurately 
model library selection conditions. The existing platform for this comparison utilizing so 
called GLF and GFA mutants of scFv anti-GCN4 has kD values that are too close to be 
discerned between [25]. Alternative mutations to the CDR3 may further reduce binding to 
GCN4 without significantly altering expression level.  
Selecting a scFv anti-GCN4 mutant with very low affinity to GCN4 may allow 
discerning between non-binding and high binding scFvs. Another option is to use scFv D10 
with GPD anchored to the membrane. A negative, non-binding control with the same 
framework, J21, does not bind to GPD and can serve as an alternative to the current scFv 
anti-GCN4/GCN4 system [46]. Parts of this alternative scheme is already cloned (ssDsbA-
GPD-ωBla-yegH and αBla-D10), leaving only αBla-J21 to be cloned. Implimentation of αBla-
J21 will hopefully increase selectable range for scFv binding above the existing O(102) 
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(Figure 2C). This simple switch to an alternative contrived scFv configuration may offer 
sufficient resolution to demonstrate selection between binding and non-binding scFvs. 
Sub	  Aim	  D:	  Alternative	  reporters.	  
While split beta-lactamase has proven effective for soluble associating pairs (Figure 
1C) [34], limitations in selection resolution may not be suited for membrane-anchored 
targets. As such, it may be worthwhile to explore alternative reporter proteins. One key 
advantage of the Bla-based reporter is the ability to function in the periplasm, permitting 
scFv targeting against extracellular domains of human proteins. When considering 
alternative reporters, periplasmic activity precludes a number of proven options including 
split mDHFR [46], split CRE [72], and split YFP [44]. A perisplasmically active mutant of 
split superfolder GFP offers a periplasmic alternative [73, 74].  
Just as with altering bait/prey configuration, exploring alternative reporters requiring 
recloning existing vectors. A split GFP format developed by Zhou uses GFP1-10, the first 10 
beta-sheets of superfolder GFP fused to the prey molecule and the engineered M12 peptide, 
an analogue to the 11th beta-sheet of GFP, fused to the bait molecule. In place of αBla and 
ωBla, GFP1-10 and GFPM12 [74] will be inserted. Earlier work has demonstrated that the 
GFP1-10/M12 reporter configuration yields a detectable signal with Fos/Jun bait/prey 
fusions (not shown). GFP1-10 will be genetically fused to the scFv, while the M12 peptide 
will be inserted in place of ωBla to form ssDsbA-GCN4-M12-yegH. Similar controls to 
previous cases will be employed in an effort to discern between high and non-binding cases. 
Specific	  Aim	  2:	  Screening	  scFv	  Libraries	  Against	  Transmembrane	  Proteins	  
The goal of developing conditions that discern between binding and non-binding 
scFvs leads to being able to screen scFv libraries against membrane proteins to select 
binding members. This aim proceeds in a series of three cases, building to the ultimate goal 
of engineering antibodies against arbitrary transmembrane proteins. First, a contrived 
library that has been demonstrated to function in other selection systems [25] will confirm 
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that the selection is able to create desirable results. From there, a naïve library may be 
screened against native E. coli proteins that are understood to have high expression levels 
and tolerate fusion proteins. Finally, scFvs will be engineered against interesting and 
biotechnologically relevant membrane proteins. 
Sub	  Aim	  A:	  Contrived	  membrane	  linked	  antigen	  substrates	  
Before true naïve libraries can be screened, a previously characterized library will 
demonstrate the ability to select known binding members. Previous studies in the DeLisa 
laboratory, have selected libraries of scFv anti-GCN4 against a GCN4 epitope using the FLI-
TRAP selection scheme [25]. In Waraho’s study, an NNK library of three residues in CDR3 of 
scFv anti-GCN4 was constructed and screened to select high binding mutants. Following a 
similar methodology, this project seeks to screen the same NNK library of CDR3 of scFv 
anti-GCN4 against the existing GCN4-ωBla-yegH to find scFvs that bind to GCN4. Known 
high binders have a GLF motif in the CDR3 domain, while non-binding or low-binding 
mutants have other sequences, GFA is one such well characterized low-binding mutant [25]. 
Testing positive hits against a negative control of ωBla-yegH will ensure that members bind 
only to GCN4. 
The library of scFv anti-gGCN4 NNK CDR3 has already been created and sequencing 
was underway. Pending confirmation of library size and diversity, a series of trial selections 
of library members will be used to determine conditions that yield desired numbers (O(10)) 
of colonies, as in [25]. Selected colonies will be retransformed and screened to determine 
precise resistance, and high resistances will be assumed to be false positives. Positive hits 
suspected to be true results will be cloned into fresh vectors via PCR and rescreened against 
target and negative controls to show that members bind only to the GCN4 epitope. 
Recloning makes sure that no recombination events reconstitute full length Bla between the 
two vectors. Further characterization in vitro will confirm direct binding to the target region, 
and provide affinity measurements. 
Sub	  Aim	  B:	  Antibodies	  against	  native	  E.	  coli	  transmembrane	  proteins	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It is best to screen naïve libraries against membrane proteins with well-characterized 
proteins that are known to express at high levels in E. coli. Selection of high expression 
targets ensures that weak signals can be attributed to non-binding rather than an absence 
of target molecule. Moreover, it is important to select targets that are less toxic to cells, and 
native proteins often satisfy this requirement. In this line of thinking, Skretas and Georgiou 
selected yegH as their native E. coli membrane protein anchor for their membrane protein 
folding reporter [47].  
To find antibodies against membrane proteins, ssDsbA-ωBla-yegH will be expressed 
as the target protein. Binding of an scFv-αBla prey molecule to yegH will reconstitute full 
length Bla, lending antibiotic resistance. As with the contrived anti-GCN4 scFv library, 
successful binding scFvs will be recloned into fresh vectors to confirm binding. In addition to 
confirming antibiotic resistance with the selection target of ssDsbA-ωBla-yegH, a negative 
control of ssDsbA-ωBla will serve to remove any library members that might bind to ωBla or 
a linker sequence. Successful scFv mutants that yield resistance when expressed with 
ssDsbA-ωBla-yegH, but not ssDsbA-ωBla, will be further characterized in vitro to 
demonstrate and measure binding. 
Sub	  Aim	  C:	  Antibodies	  against	  biotechnologically	  relevant	  transmembrane	  proteins	  	  
With the ability to target antibodies against native E. coli proteins, targeting 
antibodies against an arbitrary transmembrane protein target is limited only by the ability to 
express target proteins. Chief targets include OSTs and GPCRs for their importance in 
biotechnology, and ability to be expressed and purified in E. coli. A range of bacterial and 
the only reported eukaryotic OST have been expressed in this project. Earlier work in the 
DeLisa laboratory successfully expressed a range of human GPCRs from [75]. Balancing 
expression level with cell stress of overexpression will present another challenge. Examples 
from Skretas [47] clearly illustrate that there is no universal method for improving 
expression of membrane proteins.  
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Lacking a guaranteed method to improve expression without increasing toxicity, 
tuning expression levels will require a heuristic approach for each individual family of 
membrane protein. Such techniques will begin with simple optimization of growth 
conditions, strain, and expression plasmid. It is expected that these techniques will be 
sufficient for the inhouse GPCR (CB1, CB2, BR2, and NKR1 [75]) and OST (C. jejuni, C. lari, 
D. vulgaris, D. gigas, and L. major) since their expression can already be detected in 
membrane fractions (not shown). Further optimization of membrane protein expression 
level will demand implementation of a selection platform, as espoused by Skretas [47]. 
Tuning scFv library expression will also prove beneficial, because carefully tuning 
stoichiometry of bait-prey reporter assembly interactions can improve resistance. This is 
achieved through implementation of alternative expression vectors for the αBla-scFv 
construct. Highly tunable tet-promoter based vectors are desirable in a case like this, since 
they permit a broad range of expression levels. Such vectors are likely to be implemented 
to overcome current failures to create sufficient selectable range, so minimal cloning will be 
required to optimize expression level for each new membrane protein target. 
Specific	  Aim	  3:	  Develop	  in	  vitro	  Assay	  to	  Confirm	  Binding	  of	  scFvs	  to	  Membrane	  
Targets	  
To ensure that selected resistance phenotypes are the result of specific binding 
interactions, binding must be confirmed in vitro. Purified scFvs and target membrane 
proteins will be used to show that the antibiotic resistance phenotype is not an artifact of an 
alternative or non-specific binding interaction. The primary options available are: Enzyme-
linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). These methods 
offer a means for measuring scFv binding outside the context of the PCA machinery and cell 
milieu.  
ELISA or SPR with membrane proteins begins with purification of detergent 
solubilized targets, a process which will borrow proven techniques from the OST project. 
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Native E. coli proteins will be purified by applying techniques developed for more difficult, 
exogenous membrane proteins (See OST characterization chapter). Initial targets for naïve 
libraries will be constrained to those that have been purified effectively—namely 
oligosaccharyl transferases and GPCRs. With the exception of methods used to purify 
membrane protein targets, in vitro scFv binding measurements rely heavily on long 
established and well-understood methods [76, 77]. 
Sub	  Aim	  A:	  Enzyme-­‐Linked	  Immunosorbent	  Assay	  (ELISA)	  
A common way to confirm that selected scFvs are true positives is the Enzyme-
Linked Immunosorbent Assay (ELISA) [24]. In this assay, the target membrane protein is 
purified and captured on the solid phase of a 96-well plate, and is incubated with the 
purified scFv. Binding of the target protein to the immobilized scFv can be detected by 
probing against a tag specific to the target protein [76]. In this format, membrane proteins 
are incubated on coated ELISA plates to immobilize them on the surface. Next, a scFv with 
a unique protein tag is incubated with the immobilized protein and, after rinsing away 
excess, is detected with an antibody specific for the unique tag. This technique may detect 
binding, and can even be used to compare binding of different variants of an scFv [24]. 
Sub	  Aim	  B:	  Surface	  Plasmon	  Resonance	  (SPR)	  
Surface plasmon resonance makes use of a highly sensitive optical detection scheme 
to measure binding of molecules near a high precision gold surface [78]. Measuring the 
index of refraction of an incident laser on a gold surface, it is possible to detect minute 
changes in interface properties. This technique has been applied to antibody binding to 
protein targets [77] and for detecting ligand binding to immobilized membrane proteins 
[79].  
To demonstrate binding of selected scFvs, two schemes of detection may be 
employed: immobilized membrane proteins and scFv captured, or immobilized scFvs with 
membrane protein captured. Membrane proteins may be immobilized in a number of ways 
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including antibody capture of detergent solubilized membrane proteins [79, 80]. 
Additionally, NTA may be used to immobilize His-tagged membrane proteins [81]. 
Conversely, scFvs may be immobilized using either free-amine coupling or His-NTA [82]. 
High sensitivity has been achieved detecting small molecule binding to immobilized GPCR 
targets [80, 81], making detection of macromolecules like scFvs a probable outcome.  
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Expression, Purification, and Characterization of Oligosaccharyltransferases 
in Escherichia coli 
A scalable platform for OST expression and purification from E. coli has been 
developed and preliminary characterization of C. jejuni PglB demonstrated. Further 
applications of these techniques will allow new levels of understanding for not only the well 
understood C. jejuni and C. lari OSTs [31, 50, 53, 56], but also interesting and valuable 
OSTs that appear to have relaxed or altered substrate specificity (Guarino unpublished). In 
addition to investigating protein substrate preferences, the developed immunoblot and 
peptide fluorescence assays allow investigation of OST lipid and glycan requirements. 
Characterization of substrate requirements allows a number of expanded applications 
including therapeutically relevant sugars and a variety of glycan-linked reporters. 
Specific	  Aim	  1:	  Purification	  of	  new	  OSTs	  
Sub	  Aim	  A:	  R331	  PglB	  mutants	  
Mutations to R331 in C. jejuni PglB alter protein substrate specificity in vivo by 
changing the hydrogen bonding pattern between the OST and its substrate(Figure 7C) 
(Guarino, unpublished). It is unclear whether this mutation has consequences for expression 
level, substrate binding strength, or catalytic activity. It is hypothesized that this mutation 
modifies the enzyme’s ability to bind the substrate, since R331 forms a hydrogen bond with 
the -2 residue of the protein substrate (Figure 7B) [31]. Expression and purification of 
mutants with altered specificity will offer insight into how the enzyme interacts differently 
with the substrate. Combining in vitro assays with binding studies, the efficiency of binding 
and catalysis can be measured. This also serves as a platform to engineer variants of C. 
jejuni PglB with different protein specificities, which could allow different glycans to be put 
on a single protein. For example, a protein can be glycosylated at DQNAT in vivo, then 
purified and glycosylated at AQNAT in vitro, yielding a protein with two distinct glycans. 
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To evaluate the activity of these enzymes, select R331X mutants will be transformed 
into C43 cells, and evaluated for expression just as PglB has been previously. With 
successful expression, enzymes will be purified and tested for activity on tamra-labeled 
DQNAT and AQNAT sequon peptides. Enzymes will be compared for rate and extent of 
glycosylation under a variety of concentrations of substrate. The goal of these experiments 
is to confirm in vivo findings about the ability of R331X variants to glycosylate AQNAT in 
vitro. 
Sub	  Aim	  B:	  OSTs	  from	  other	  bacterial	  species	  
Recent work in the DeLisa laboratory has uncovered some evidence that a number of 
OSTs from the Desulfovibrio genus are able to glycosylate a Eurkayotic-like acceptor site 
AQNAT in vivo (Guarino, unpublished). To confirm this relaxed acceptor site specificity, D. 
vulgaris has been purified and reacted in vitro with peptide substrates. Two more enzymes 
from D. gigas and D. desulfuricans appear to have similar activity [29] and preliminary 
evidence indicates that D. gigas has similar performance to D. vulgaris. To date, D. 
desulfuricans has evaded purification. 
Here, the scheme follows as before, evaluation of expression is followed by 
purification of target OSTs. Successfully purified OSTs will be evaluated for ACRA, R4-4xGT 
and peptide reactions will be used to investigate folding state requirements of each enzyme. 
Acceptor site sequence requirements will be conducted using peptide assays to rule out the 
influence of steric constraints. Peptide assays will also be used to calculate rates and 
evaluate LLO preferences by measuring extent of glycosylation over a short time course. 
Ideal OSTs have higher catalytic rates and eukaryotic-like sequence specificity 
compared to the current standard of C. jejuni PglB. Sequences of candidates can be aligned 
with well-characterized OSTs to evaluate the role of mutations in variable regions on 
catalytic activity and substrate binding. Preliminary evidence shows high conservation in 
substrate binding and catalytic domains (Supplemental Figure 1B), but it remains unclear 
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which domains are most important to improve performance.  Such insights could be 
valuable for creating chimeras with high catalytic rates and specifically designed substrate 
binding. 
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Supplemental Figure 1: (A) Distance tree of OSTs (above) and acceptor sites 
(below). OST distance trees are calculated based on sequence identity and assembled using 
Molecular Evolutionary Genetics Analysis. (Tamura, Stencher, Peterson, Filipski, & Kumar, 
2013). Glycosylation sequence distance is calculated as the probability for enrichment of a 
specific amino acid in the X1 and X2 residues (-1 and +1 relative to the asparagine residue) 
in context of a glycosylation site compared to an arbitrary asparagine residue for bacterial 
hosts. (B) Conversation of residues in bacterial OSTs mapped onto the three dimensional 
structure of C. lari PglB from (Lizak C. , Gerber, Numao, Aebi, & Locher, 2011). Highly 
conserved regions (maroon) tend to be focused in the catalytic cleft (maroon pocket in 
center), while outer regions, as expected, tend to be highly variable. A degree of variability 
near R331 and R332 permits invites expectation of differences in substrate specificity. (C) 
calibration curve of peptide fluorescence in Tris-Tricine SDS PAGE gels. A simple dilution 
series illustrates a direct correlation between concentration and signal strength over several 
orders of magnitude and sets a minimum detection threshold on the order of single pmol of 
peptide.  
Sub	  Aim	  C:	  eukaryotic	  OSTs	  
Studies suggest that eukaryotic OSTs are highly sensitive to steric hindrance of the 
protein substrate and to the identity of the LLO lipid carrier [51, 54]. Further in vitro 
characterization of L. major STT3A will help to expand understanding of not only this 
enzyme’s properties, but also eukaryotic OSTs in general. Relatively little is known about 
eukaryotic OST substrate specificity and LLO requirements [5]. The current three model 
protein substrates allow investigation of structured, loosely structured and unstructured 
domains, which will be useful in tuning reaction conditions. eukaryotic LLOs are desirable in 
biotechnology in their ability to place eukaryotic glycans on eukaryotic acceptor sequences 
[5, 30]. 
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Further characterization of L. major STT3A will begin with purified R4-GT, to see if 
the enzyme is able to glycosylate loosely structured domains. Since eukaryotic OSTs are 
known to associate with the sec translocon and glycosylate cotranslocationally [51, 58] it is 
expected that eukaryotic OSTs can glycosylate loosly structured domains. More detailed 
peptide assays with an expanded set of LLOs will begin to investigate lipid and glycan 
requirements for the enzyme. At present, only C. jejuni LLOs have been evaluated, and C. 
lari and W. succinognenes are likely next targets. Advances in LLO preparation (Specific Aim 
3) will enable use of eukaryotic LLOs as well. 
A number of eukaryotic OSTs are closely related to the L. major OSTs, specifically 
those from the Trypanosoma genus. OSTs from T. cruzi and T. bruci will be cloned into 
bacterial expression vectors. These OSTs will be evaluated for expression and purification. 
Targets that are successfully purified will be characterized for their substrate specificity, 
paralleling work with L. major STT3A and bacterial OSTs.  
Specific	  Aim	  2:	  Characterization	  of	  lipid	  requirements	  
Lipid requirements for OST function have been characterized only in limited ways, 
often using crude membrane isolates rather than purified OSTs [50, 59]. Peptide based in 
vitro characterization of purified OSTs allows precise control of LLO, enzyme and substrate 
concentrations in ways that are impossible in vivo or with crude membrane fractions [55]. It 
is possible to examine precise LLO requirements for OSTs in terms not only of 
concentration, but also phase behavior, and identity. 
The Imperiali lab has succeeded in isolating isoprenoid species from plants and 
testing their function as a substrate with C. lari PglB [50]. Similarly, the Davis lab has been 
able to synthesize rationally designed polyisoprenoid carriers to investigate LLO 
requirements of PglB [55]. Findings have suggested that C. lari PglB prefers unsaturated 
head groups [50, 55], while investigations in yeast have demonstrated a preference for 
saturated head groups in eukaryotic OSTs [59]. 
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Sub	  Aim	  A:	  Lipid	  phase	  behavior	  
It has long been established that lipid phase behavior is highly sensitive to even 
small changes in concentration or hydropathy [8]. Despite the recent publishing of a crystal 
structure of C. lari PglB, it is unclear how the lipid carrier binds to the hydrophobic domain 
of the OST [31]. Early results have indicated that LLO concentrations above critical levels 
decrease glycosylation efficiency (not shown). Moreover, the integration of LLOs into OST-
harboring detergent micelles is an uncharacterized that is open to optimization. 
Phase behavior can be evaluated with varying concentrations of detergent, lipid 
carriers, and LLOs in the reaction mixture [8]. Light scattering or small angle X-ray 
scattering measurements can lend insight into lipid phase behavior with varying 
compositions, for example dispersed, micelle, or bicelle behavior [83]. Current theory 
predicts that purified membrane proteins are present in detergent micelles, but it remains 
unclear how LLOs integrate into these micelles and bind to OSTs. Detailed investigation of 
lipid exchange kinetics with the use of radiolabeled lipids can lend insight into interactions 
between LLOs and OSTs in vitro [84]. Such experiments, however are difficult and not 
suited to work in the DeLisa lab. 
Detergent identity is easily investigated with modifications to the buffers used to 
purify protein and the reaction buffer. Other target detergents are DDM [32, 64], 
zwitterionic detergents and other maltopyranosides [8, 85]. Concentrations in the reaction 
mixture are trivial to change, and approximate estimates for detergent phase behavior 
(critical micelle concentration, aggregation number, etc.) available from suppliers lend 
insight for choosing ranges of conditions. These experiments are to be conducted by 
creating reaction mixtures with detergent concentrations in three main phase domains: 
dispersed, micelle, and bicelle. 
Lipid carriers (non-glycan-conjugated polyisoprenols) can be isolated from E. coli 
SCM6 harboring and empty pACYC plasmid [32]. Alternate options include pglΔFEDC 
plasmids, which don’t express the genes to build undecaprenol-bacilosamine pyrophosphate 
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[86], yielding unlabeled undecaprenol. Mixing LLO carrying membrane fractions with 
polyisoprene species lacking glycans allows the concentration of LLO to remain constant 
while changing the total polyisoprene concentrations. Such variations may alter phase 
behavior or interactions between polyisoprene and detergent micelle phases. 
Sub	  Aim	  B:	  Alternate	  polyisoprene	  LLO	  substrates	  	  
In addition to C. jejuni and C. lari pgl loci, W. succinogenes and a few other bacterial 
pgl loci have been cloned into pACYC vectors. Transforming these plasmids into SCM6 cells 
allows isolation of LLOs from an arbitrary bacterial species. With a large diversity of 
bacterial glycans, it becomes possible to investigate if OSTs have preference for glycan 
types. Evidence of glycosylation of O-antigens onto AcrA by C. jejuni PglB suggests that 
glycan size alone does not inhibit glycosylation [87]. However, O-antigens tend to be highly 
linear and little is known of PglB’s ability to use highly branched glycans beyond studies with 
simple eukaryotic glycans [30]. Full eukaryotic glycans tend to be highly branched, which 
may create problems. Only limited branching of yeast glycans have been examined so far. 
Because antibodies against glycans tend to be highly specific, it may be possible to 
perform competitive glycosylation and evaluate preference for one glycan over another. 
However, the highly variable nature of antibodies requires a thorough calibration and 
quantification to ensure that comparisons are valid. However, if glycans are different sizes, 
or significantly change peptide migration rate through a gel matrix, it may be easy to 
evaluate glycosylation efficiency using the simpler peptide fluorescence assay. 
Bacterial OSTs could possibly use eukaryotic LLOs in vitro. This allows LLOs to be 
prepared from an organism that offer a higher yield or homogeneity of specific glycans than 
current bacterial systems, namely yeast. Using the bacterial OST’s ability to glycosylate 
folded proteins and eukaryotic LLOs allows eukaryotic core man3 glycans to be added with 
high efficiency to purified proteins. Other LLO targets may have glycans that can not 
presently be synthesized in bacteria, sialylated human glycans, for example. 
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Specific	  Aim	  3:	  Glycosylation	  with	  therapeutically	  relevant	  and	  labeled	  sugars	  
Current projects in the DeLisa lab are focusing on the use of synthetic sugars with 
interesting functional groups. Azido sugars like Ac4GlcNAz and Ac4GalNAz can be integrated 
into bacterial N- and O- glycans (Stevenson, unpublished). Such sugars can be 
functionalized with the use of copper-free click chemistry. Copper-free click chemistry allows 
labeling of any azide group with a diverse range of chemical labels under physiological 
conditions. Reaction between a DIFO motif with attached functional group and an azido 
sugar yields a covalent linkage between sugar and desired functional group. 
Sub	  aim	  A:	  glycosylation	  with	  eukaryotic	  sugars	  
eukaryotic glycans are of particular interest in therapeutic applications. Recent in 
vivo studies have shown that C. jejuni PglB is able to glycosylate AcrA with undecaprenol-
linked Man3 core eukaryotic glycan [30]. Other findings suggest that C. jejuni PglB is able 
to use dolichol as a substrate, albeit at 25% the rate of undecaprenol-linked glycans [50]. 
There are thus two ways to isolate LLOs with eukaryotic glycans: synthesis in E. coli and 
extraction from eukaryotic sources.  
At present, yields of the Man3 core eukaryotic glycan in E. coli are low and 
homogeneity is poor. This is likely due to poor expression of the Saccharomyces cerivisae 
enzymes responsible for the synthesis [30]. With improved yield of these glycans on LLOs, 
E. coli based synthesis of eukaryotic LLOs will become a viable option. For the foreseeable 
future, E. coli remain a platform suitable for synthesis of bacterial LLOs. Eukaryotes will 
have to suffice as a source of eukaryotic LLOs. 
Methods for isolation of large quantities of relatively high purity and high 
homogeneity LLOs have long been established [50, 88]. Preliminary results suggest that 
existing in-house methods are able to isolate LLOs, albeit with low yield and low purity. 
Refinement of this technique will allow use of OSTs to glycosylate peptides and proteins with 
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fully formed yeast core glycans. While many bacterial glycans have good antibodies against 
them, eukaryotic glycans rely on lectins for identification [30]. 
Sub	  aim	  B:	  labeling	  with	  Azido	  sugars	  
If LLOs with Azido sugars are viable substrates for OSTs, a number of extraordinary 
new protein labeling techniques become available. Potential labels include protein tags, 
fluorescent labels, detergents, and virtually any active group imaginable. Protein tags are 
useful for capture and purification, and can even be used to create branched proteins or 
scaffolding enzymes. Virtually any fluorescent tag can be attached to a DIFO motif, allowing 
specific addition of easily identifiable tags, rapid imaging, and simple measurements of 
glycosylation efficiency. Conceivably, detergents or acyl groups can be attached specifically 
to N-glycans to produce acylated proteins that can anchor in cell membranes, or assemble 
into small clusters.  
Sugar labeling offers a number of advantages over current chemical labeling and 
unnatural amino acid techniques. Chemical labeling tends to be either non-specific for amine 
or carboxyl groups, or limited to the termini of a protein. Glycosylation ensures that labels 
are attached within the specific sequence. Unnatural amino acid additions typically rely on 
an amber-suppressor mutation and have low incorporation rates[89]. By contrast, in vitro 
glycosylation has high efficiency (upwards of 80% for peptides, Figure 6) and high 
specificity.  
Simple demonstrations of in vitro labeling of proteins with N-linked azido sugars is 
performed by isolating LLOs from SCM6 cells harboring the pglΔB plasmid and fed either 
Ac4GlcNAz or Ac4GalNAz. The resulting LLOs will be used in a peptide reaction mixture in 
place of wild type C. jejuni LLOs. Reactions will be boiled to denature PglB and click 
chemistry will be employed in the reaction mixture to add a fluorescein dye to the azide 
group. Peptides will be run on a gel as in established protocols, and imaged using a 2-color 
capable imaging system to discern between red TAMRA-labeled peptides and green 
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fluorescein-labeled sugars. Successful labeling will be demonstrated by coinciding red and 
green bands corresponding to the mass of a glycan conjugated to a peptide. 
Sub	  aim	  C:	  labeling	  with	  fluorescent	  labeled	  sugars	  
LLOs can be labeled with fluorescent dye molecules before being used as reagents in 
an in vitro glycosylation reaction. In this case, proximity of TAMRA molecules on peptides 
and fluorescein labeled sugars can be calculated with Forester Resonance Energy Transfer 
(FRET) measurements. FRET is the non-radiative energy transfer between two 
chormaphores. Energy transfer from the donor chromaphore is able to excite the receptor, 
which releases a photon upon relaxation. In practical terms, illumination with a wavelength 
that excites one chromophore yields fluorescence of the second chromaphore at a rate that 
is proportional to the distance and alignment of the two molecules, and overlap of the 
absorbtion spectra. TAMRA and fluorescein are well-characterized FRET pairs, with a R0 of 
55nm, or a distance of roughly 4 amino acids and half the length of the C. jejuni glycan. 
Glycosylation of a TAMRA-labeled peptide with a fluorescein-labeled glycan will yield an 
increase of FRET signal, allowing real-time measurements of glycosylation rates. 
Specific	  aim	  4:	  Kinetics	  
Current descriptions of PglB kinetics rely on a simple Micalis-Mentin model [56]. This 
model ignores the enzyme’s dual substrate nature and keeps LLO concentration fixed. A 
more accurate consideration of the substrate binding kinetics and enzymatic action can give 
rise to a more detailed understanding of not only overall enzymatic action but also binding 
domains for specific substrates. At present, it is not known if the order of substrate binding 
is important. A detailed kinetic understanding that is able to control availabilities of both 
substrates will be an important step in understanding the precise kinetic mechanism of 
OSTs. Moreover, a better understanding of kinetic mechanisms allows the consequences of 
mutations to be better understood.  
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Advanced optics techniques like fluorescence anisotropy allow measurement of 
substrate binding in real time. Fluorescence anisotropy measures polarized fluorescence, 
effectively measuring a molecule’s rotational diffusion. Such techniques were used to 
measure peptide substrate affinity of PglB [56], but have yet to be applied to LLO binding. 
Use of fluorescence anisotropy with fluorescent labeled peptides and glycans allows 
calculation of binding rates for both substrates to be calculated. FRET based real-time 
catalytic rate measurements and fluorescence anisotropy together allow measurement 
allows the measurement of the binding rates for both substrates, catalytic rates and product 
release rates. In short, these techniques enable a complete kinetic characterization of OSTs. 
The peptide-based assay also allows evaluation of efficiency against rationally 
designed peptide substrates. Peptides can be designed for predicted binding characteristics 
like solvation energy and flexibility by selecting amino acid sequences or even 
peptidomimetic residues for desired binding cleft characteristics. Energy of solvation may be 
tuned to change the affinity of the peptide for the catalytic cleft of PglB, which allows 
evaluation of a potential new model for enzyme-substrate interaction. 
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